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Abstract 
A paucity of information exists on the benefits of using radiation therapy for treating women 
with early cervical cancer detection. The purpose of this cross-sectional study was to 
investigate the association between early versus late testing of Human papilloma virus 
(HPV), age, race, radiation therapy, and regions in United States, and survival rates among 
women diagnosed with early cervical cancer. The epidemiological triad of person, time, and 
space guided this study to explain the regional spread of cervical cancer, and the effect of 
early testing. Secondary data from Surveillance, Epidemiology, and End Results (SEER) 
were used (N= 520,153). Statistical analyses included descriptive statistics as well as binary 
and multiple logistic regression. According to multiple logistic regression tests early testing 
for HPV saved more women from cervical cancer death (Odds ratio = .917, CI = .896 - .939, 
P = .000), and women with radiation therapy had increase likelihood of dying (Odds ratio = 
1.646, CI = 1.626 – 1.667, P = .000). Older Women had increased likelihood of dying when 
diagnosed with cervical cancer (Odds ratio = 1.043, CI = 1.042 – 1.044, P = .000).Whites 
had a reduced likelihood of dying when diagnosed with cervical cancer (Odds ratio = .735, 
CI = .722 - .748, P = .000) compared to non-Whites with increased likelihood of dying 
when diagnosed with cervical cancer (Odds ratio = 1.3605, CI = .722 - .748). Alaskans had 
a reduced likelihood of dying compared to women living in the Pacific Coast (Odds ratio = 
.714, CI = .598 -.853, P = .000). Increased awareness among women on radiation therapy 
for early detection of cervical cancer can improve survival and lead to positive social 
change.  
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Chapter 1: Introduction to the study 
Introduction 
The development of cervical cancer occurs from persistent, high-risk infection with 
human papilloma virus (HPV) Genotypes 16 and 18, and HPV takes 10-20 years or longer 
for the disease to develop into a malignant cervical cancer (Lin, Fan, & Tu, 2016). 
Adolescent women are at high risk of developing cervical cancer due to a lack of awareness 
of the causes of cervical cancer. Research on cervical cancer affecting young women 
remains limited. Health professionals are unable to guide adolescent women on the benefits 
of early screening and treatment options for HPV such, as radiation therapy for curing 
HPV-related cervical cancer (Lin et al., 2016).  
In this chapter, I discuss the background of the problem, the problem statement, the 
purpose statement, and a statement of the research questions and hypotheses in the study. I 
also address the need to investigate the implications of early testing and radiation therapy 
on survival rates of women with early stages of cervical cancer, based on race and age for 
women living in the United States.  
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Background 
Radiation therapy is a therapeutic component of cancer management. Baalbergen, 
Veenstra, and Stalpers (2013) stated that surgery or radiation therapy was the best option 
when treating early cervical cancer. Further, Baalbergen et al. argued that surgeons 
preferred surgery as the first step for treating cancer, but often requested subsequent 
radiation therapy for treating Stages Ia and IIa cervical cancer. Baalbergen et al. claimed 
that the therapeutic effects of treating cervical cancer with radiation were not apparent.  
There were many treatments available to women based on the stage of the disease.  
Winer et al. (2015) stated that physicians treated early stage cervical cancer (Stages 
IA to IIA) with surgery alone and the advanced stages (Stages IIB to IVB) with 
chemotherapy. However, the benefits of radiation therapy for younger women remain 
unclear. In treating early cervical cancer with surgery alone, there was a decline in survival 
rates in 2015 in the United States (Winer et al., 2015). Among women diagnosed with an 
earlier stage of the cervical cancer, 15-61% developed metastatic disease within 2 years 
with 5 year survival rate less than 5% due to surgery treatment alone (Pfaendler & Tewari, 
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2016). Surgery alone for treating early cervical cancer did not guarantee a complete cure 
(Nieder et al., 2015). Research must focus on the benefits of using radiation therapy for the 
treatment of early cervical cancer, which was the focus of this study. Nieder et al. (2015) 
reported that using radiation therapy alone or in combination with other therapies for 
treating late-stage cervical cancer did not improve survival rates. Nieder et al. did not 
include the effects of radiation based on age and race for treating early stage cervical 
cancer; thus, there remains a gap in the literature.  
Cervical cancer is a malignancy that forms in the cervix of women with the HPV 
pathogens; however, contracting the disease is mostly preventable through the practice of 
early screening tests and early vaccines (Center for Disease Prevention and Control [CDC], 
2015). According to the CDC (2015), all women are at risk of contracting cervical cancer, 
but women who are 30 years and older have an increased danger of developing late-stage 
cervical cancer when there was no early testing conducted (3-year intervals). Wright et al. 
(2015) explained that persistent infection with high-risk Genotypes 16 and 18 lead to the 
development of high-grade cervical neoplasia. Wright et al. stated that the first line 
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screening for cervical cancer is HPV testing for Genotypes 16/18 with increased sensitivity 
to detect Cervical Intraepithelial Neoplasia 3 (CIN 3+).  
There is a time difference between first abnormal cytology and diagnosis of cervical 
cancer. Zaal et al. (2015) conducted a study among women between 30 and 60 years to 
identify incubation period in the development of cervical cancer. In the first group, 50% of 
women developed cervical cancer 2 years after the first abnormal smear; and in the second 
group, 60% developed cervical cancer 5 years after the first smear (Zaal et al., 2015). It 
took approximately 3 to 5 years from the first abnormal cytology (precancerous) to the 
development of cervical cancer (Zaal et al., 2015). Early detection of precancerous lesion 
helps to prevent the development of cervical cancer.  
There is a decline in the incidence and mortality related to cervical cancer; 
however, the incidence and mortality of this disease remain high. Pfaendler and Tewari 
(2016) argued that 528,000 women worldwide had cervical cancer and mortality was 
266,000 annually, indicating that approximately 50% of all women diagnosed with cervical 
cancer die. Based on reports from the American Cancer Society, 12,900 new cases of 
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cervical cancer occurred in 2015 in United States and 4,100 people died, indicating a 
mortality rate of 32% in 2015 (Pfaendler & Tewari, 2016).  
Cervical cancer cases among women increased in the United States over the last 6 
decades because of improper screening for much of the period. Kim et al. (2015) found that 
the cervical cancer screening in the U.S. was not conducted properly, causing many women 
to go untreated. Kim et al. further argued that the reduction in the cervical cancer incidence 
began with the introduction of cytology-based screening in the 1940s, which included 
various screening rates based on region. In some areas, women frequently received 
screening; in other regions, women did not test at all. Kim et al. reported that 
approximately every year 12,000 women were diagnosed with cervical cancer and 4,000 
women died from results of the diagnosis. Most of the diagnoses and deaths occurred in 
underserved communities where particular race/ethnic minorities lived (Kim et al.,2015). 
There is an approximately 10-year interval between the last Pap smear test and the 
development of cervical cancer in women (Pfaendler & Tewari, 2016). Further, 5 % of 
women diagnosed with cervical cancer in North America had Stage IV cervical cancer 
6 
 
 
 
disease with a survival rate of less than 21% (Pfaendler & Tewari, 2016). A significant 
percentage of women remain unaware of the benefits of early cervical cancer screening, 
resulting in late-stage testing, and diagnoses of late-stage cervical cancer (Carvallo-
Michelena, Rojas-Dominguez & Piscoya, 2015). Conducting the current study provided the 
necessary results for understanding the survival rate of early cervical cancer screening, and 
for closing an existing gap in the literature. 
To reduce the mortality from cervical cancer among women, there must be full 
participation by women in cervical cancer screening. Carvallo-Michelena, Rojas-
Dominguez, and Piscoya (2015) reported that the high cervical cancer death rate was due to 
a lack of female involvement in early detection of infections. The results indicated that 
early detection and stopping the development of cervical cancer is a way of reducing 
mortality rates among women. Hillard (2015) reported that the high incidence and mortality 
of cervical cancer in the United States are due to new cases of women who would not go 
for screening; mostly of the new cases are from Native Americans, Asian Americans, 
Pacific Islanders, and Alaska Natives. Women with no primary care doctors or health 
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insurance have the opportunity to obtain health coverage at an affordable rate for their 
families. Chen, Bustamante and Tom (2015) argued that uninsured migrants are offered 
extended eligibility under affordable care coverage for dependents’ coverage under family 
private health insurance up to age 26 years. This policy allows migrants to have access to 
screening and treatment.   
Cervical cancer has a pre-invasive stage, known as cervical intraepithelial neoplasia 
(CIN) detected through early testing. Dan, Hong, Haibo and Jianrong (2015) reported that 
CIN occurs when the high-risk HPV virus genome gets into the host cells, leading to 
abnormal changes in the host cells cycle. The HPV infections cause immune evasion of the 
abnormal cells for many years, making them undetected and leading to the development of 
cervical cancer (Dan, Hong, Haibo & Jianrong, 2015). There are more than 100 HPVs, but 
40 infect the genital tract, and persistent infections with Serotypes 16 and 18 could lead to 
cervical cancer (Foran & Brennan, 2015). The authors reported that HPV vaccines 
recommended for girls for ages 12 to 17 years lacked patronage due to lack of adequate 
8 
 
 
 
information, awareness, and education campaigns on health care services for early 
detection of cervical cancer (Foran & Brennan, 2015).  
The U.S. policies and recommendations for screening and vaccination for the 
prevention of cervical cancer have not improved participation of women in early screening. 
Alexander et al. (2014) explained that U. S. recommendation for HPV vaccination is 21 
years irrespective of age at sexual intercourse. The European recommendation for cervical 
cancer screening was 25-30 years, while Australia was 18 years or 2 years after first sexual 
intercourse (Alexander et al., 2014). Alexander et al. argued that the advent of the HPV 
vaccine did not change the cervical cancer screening recommendations.  
The age at which women undergo screening determines their ability to get adequate 
treatment and survive cervical cancer. Torre et al. (2015) found that testing early in life led 
to early detection of the disease, and with adequate treatment, prevented late stage of 
cervical cancer. Torre et al. did not study the effects of early detection with the use of 
radiation therapy among women of different race/ethnic groups, or age by the group, thus 
creating a gap in the literature. When sufficient numbers of vaccinated women refused to 
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participate in future screening, the behavior led to increased numbers of women developing 
cervical cancer (Alexander et al., 2014). There is a need for increased efforts to get more 
women to participate in early screening, and to give better treatment for the few who have 
early cervical cancer. In this study, I focused on the effects of using radiation therapy for 
early cervical cancer among women in United States, and reported whether radiation 
therapy would increase survival or not.  
Women who participated in the initial screening often find it difficult to complete 
all of the screening recommendations. In the United Kingdom, only 8% of women 20-22 
years of age partially completed three doses of HPV vaccinations, and only 18% of all 
women received cervical cancer screening (De Angelis et al., 2014). There is a lack of 
adherence to screening recommendations. Normal tissue cells may have cervical cancer 
cells close to the tumor site, which the surgeon’s knife might not remove (Kim et al., 
2015). Kim et al. (2015 found that treating cervical cancer with surgery alone often did not 
remove all cancer cells. The procedure often led to recurrence of cervical cancer in most 
communities in the United States (Kim et al., 2015). Sert et al. (2016) reported that surgical 
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therapy in early stage cervical cancer saves lives, but recurrence is high with an odds ratio 
of 3.15. There is a need for additional therapy, such as radiation therapy, to remove cancer 
cells that may come back as invasive cervical cancer. 
Murakami et al. (2015) reported that the introduction of radiation therapy into 
gynecological malignancies started in the recent decade; however, there was no study 
validating the effect of radiation therapy on gynecological malignancies. Murakami et al. 
stated that the tools are available to deliver adequate doses of radiation to gynecological 
target tissues while avoiding the nontargeted tissues. For example, the effectiveness of 
targeted radiation therapy occurred in prostate cancer and in the cancer of the head and 
neck; however, the treatment efficacy in cervical cancer was unclear (Murakami et al., 
2015). Finding cervical cancer late puts women at high risk of mortality. Landoni et al. 
(2014) found that radiation therapy did not offer improvement for women because the 
disease spread to multiple organs. Landoni et al. however, did not examine the benefits of 
early radiation therapy for women of different race/ethnic groups who test early and show 
positive for cervical cancer.  
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Maguire, Kotronoulas, Simpson, and Paterson (2015) explained that a lack of 
information about the effectiveness of radiation therapy and surgery treatment existed for 
women of younger age groups diagnosed with cervical cancer. Maguire et al. found that the 
lack of information caused women to believe that surgery alone was enough to cure 
cervical cancer and delayed further screening, only to find that cancer returned during later 
testing. Maguire et al. believed that women needed more information about the short and 
long-term benefits of radiation therapy when diagnosed with early cervical cancer. 
De Angelis et al. (2014) reported that survival of cancers associated with the breast, 
the rectum, non-Hodgkin lymphoma, the prostate, the ovaries, the kidney, the colon, the 
stomach, and the lung vary by regions in the world. Survival in Eastern Europe is low and 
is below the European average, while survival in Central, Northern, and Southern parts in 
Europe was high (De Angelis et al., 2014). The survival rates of cancers are intermediated 
in Ireland and United Kingdom (De Angelis et al., 2014). De Angelis et al. did not estimate 
the survival of cervical cancer on age and early testing using radiation therapy. Borras et al. 
(2015) argued that there are improvements in survival for people diagnosed with prostate, 
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breast, and lung cancers using radiation therapy; however, survival rates of women with 
cervical cancer remains unclear.  
Scholars have indicated advancement in treating all forms of cancer. Although there 
were improvements in the treatment of women diagnosed with cervical cancer, there was a 
need for more studies to understand the effectiveness of using radiation therapy. The 
purpose of the study was to explain differences in outcomes for early diagnosis of the 
disease. The treatments were for women by age group and race, when using radiation 
therapy compared to surgery alone for treating cervical cancer. 
Problem Statement 
Globally, for every 530,000 diagnoses of cervical cancer, 275,000 people died, 
demonstrating a survival of only 48% annually (Pimenta, Galindo, Jenkins, & Taylor, 
2013). Torre et al. (2015) reported that cervical cancer was the third most common type of 
cancer among women, after lung and breast cancers, and the fourth common cause of death 
globally among all cancers. Zeng et al. (2015) reported that there had been a steady 
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improvement in cancer survival, but the improvement in cervical cancer according to age, 
sex, and race remains unaccounted for in current literature.  
There is a dearth of information among epidemiologists on the effects of treating 
early stage cervical cancer with radiation for increasing patient survival among the 
different age groups and races in the United States. Ellinor et al. (2015) argued that public 
health epidemiologist must advise women to receive early cervical cancer detection 
assessments. Torre et al. (2015) found that the burden of cervical cancer has increased due 
to U. S. women of different race/ethnic groups who had increased morbidity and mortality 
related to HPV infection. There remains a lack of current studies on the effects of radiation 
treatment on early cervical cancer among women based on race groups and age groups 
living in the United States.  
Some women received screening early in life but do not receive subsequent 
screening because of a lack of mechanisms in place to receive additional screening. Ellinor 
et al. (2015) further argued that there are benefits for women from 23-50 years who receive 
screening every three years, and for women, 51-60 years old, who receive screening every 
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five years. The results indicated that cervical cancer developed in women due to lack of 
regular screening and that early screening was necessary for increasing the survival rates of 
women. There is an absence of existing research showing the effects of early testing and 
related early radiation therapy on survival rates among women. Researchers found that 
using radiation therapy in early breast and lung cancer treatment in the U. S. was effective 
for respective survival rates. However, such information is lacking with using radiation 
therapy for treating early cervical cancer stages among women in the U.S. compared to 
surgery alone (Robinson et al., 2014).  
Purpose Statement 
The purpose of this quantitative, cross-sectional study was to examine the 
association between radiation therapy (yes, no) and early detection of HPV, race (four 
categories), age (four groups), and five regions as the independent variables and survival 
rates (two classes) as the outcomes. Researchers need to understand the effects of radiation 
therapy on early stage cervical cancer based on women’s age by group and race. Currently, 
there is unawareness of the survival effects of using radiation therapy for treating early 
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cervical cancer stages among women in the United States compared to surgery alone 
(Robinson et al., 2014). The intent of this study was to add to the body of knowledge and to 
close a gap in the literature on the effects of using radiation therapy for early cervical 
cancer and survival rates among women in the United States. 
Research Questions and Hypotheses 
The following research questions and the accompanying hypotheses were used to 
analyze the associations between the independent variables and the dependent variables.  
RQ1: What is the association between testing (early HPV VS late HPV) and 
survival rate of women when diagnosed with Stage IA to IIA cervica l cancer? 
Ho1 : There is no association between testing (early HPV VS late HPV) and 
survival rate of women when diagnosed with Stage IA to IIA cervica l cancer? 
Ha1: There is an association between testing (early HPV VS late HPV) and survival 
rate of women when diagnosed with Stage IA to IIA cervica l cancer? 
RQ2: What is the association between age and survival rates of women when 
diagnosed with Stage I to IIa cervical cancer?  
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Ho2: There is no association between age and survival rates of women when 
diagnosed with Stage I to IIa cervical cancer.  
Ha2: There is an association between age and survival rates of women when 
diagnosed with Stage I to IIa cervical cancer.  
RQ3: What is the association between race and survival rates when diagnosed with 
Stage I to IIa cervical cancer? 
 H03: There is no association between race and survival rates when diagnosed with 
Stage I to IIa cervical cancer. 
  Ha3: There is an association between race and survival rates when diagnosed with 
Stage I to IIa cervical cancer.  
RQ4: What is the association between radiation therapy and survival rates of 
women when diagnosed with Stage I to IIa cervical cancer? 
H04: There is no association between radiation therapy and survival rates of women 
when diagnosed with Stage I to IIa cervical cancer. 
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Ha4: There is an association between radiation therapy and survival rates of women 
when diagnosed with Stage I to IIa cervical cancer. 
 RQ5: What are the associations between five regions in the United States and 
survival rates of women when diagnosed with Stage I to IIa cervical cancer.  
 H05: There are no associations between five regions in the United States and 
survival rates of women when diagnosed with Stage I to IIa cervical cancer. 
 Ha5: There are associations between five regions in the United States and survival 
rates of women when diagnosed with Stage I to IIa cervical cancer.  
The two levels of HPV testing (early, late), radiation therapy (yes, no), four 
categories of race (Black, White, Hispanics, and Asians), four levels of age groups (20-29, 
30-39, 40-49, >50), five regions (Alaska, East, Northern Plains, South West, Pacific coast ) 
in United States constituted the independent variables. The dependent variable was two 
levels of survival rates (survived, not survived). 
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Theoretical Framework 
The theory of epidemiological triad of disease model was the theoretical framework 
for the study. According to Cohen and Shang (2015), Clark's 1954 developed 
epidemiological triad to explain a spatiotemporal relationship between three areas known 
as the agent, the host, and the environment. Cohen and Shang found that Clark's theory was 
useful for breaking disease transmission by predicting the agent (procedures such as early 
HPV - testing), the host (age and race), and the environment or place (regions in United 
States). Cohen and Shang believed that a triad was a form of isolation precautions useful 
for the control of infectious diseases with increased morbidity and mortality outcomes.  
The theory is useful when testing multiple interventions based on pathogens in a 
cross-sectional study. Rohrer, Grover and Moats (2013) applied the epidemiological triad 
to medical care studies and argued that researchers should use variations of the theory to 
person, place, and time associated with the theoretical model. Chaney and Rojas-Guyler 
(2015) argued that a triad is a tool that explains health promotion, educational research, and 
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practice; thereby, it is useful when analyzing health disparities across age, geographical 
regions, and access to health care.  
The epidemiological triad provides utility when explaining the health outcome 
surveillance and risk analysis for women who receive early HPV testing. A diagram of the 
theoretical model is in Figure 1. The diagram demonstrates a spatiotemporal relationship 
and shows the mode of transmission of infective agents within women (person or host). 
The diagram also shows the possible ways of stopping the disease transmission (early 
detection, radiation therapy, drugs, surgery) in a region (United States). Using the triad as 
the theoretical framework for the study provided understanding of early HPV testing as 
related to reducing mortality and increasing their quality of life.  A summary of constructs 
about the study variables is in Table 1. 
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Spatio-Temporal
Relationship
Host – [Person or 
Community]
Women ages 20-
29, 30-39, 40-49, 
>50, race
Agent- [Procedure 
or Drugs]
Early HPV Testing
Place/Geographical 
location
(exposure)
Regions in U. S.
Epidemiological Triad Theory 
 
Figure 1. A model is showing a connection between spatiotemporal relationship and 
epidemiological triad. Adapted from "Spatial analysis methods for health promotion and 
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education" by R. A. Chaney and L. Rojas-Guyler, 2015, Health Promotion Practice, 16, p. 
5. 
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Table 1  
Theory of Epidemiological Triad 
Constructs Variable Treatment Survival 
Agent or Time 
(Procedure or Drug) 
Early HPV Testing 
(Year) 
Early HPV testing 
 
Late HPV testing 
(Year) 
Radiation therapy 
 
No radiation therapy 
 
Radiation and surgery 
Unknown 
 
Unknown 
 
Unknown 
 
Host  
(person, community) 
 
Age 
 
 
 
Race 
 
Age 
(20- 29, 30-39, 40-49, 
>50) 
 
Race 
(Black, non-Hispanic 
White, Hispanic, and 
Asians) 
Radiation therapy 
 
No radiation therapy 
 
Radiation and surgery  
Unknown 
      
Unknown 
 
Unknown     
           
 
Place/Geographical 
location (Exposure) 
 
 
 
Regions in U. S. 
(Alaska, East, Nothern 
Plains, South West, 
Pacific coast)  
  
Radiation therapy 
 
No radiation therapy 
 
Radiation and surgery 
Unknown 
 
Unknown 
 
Unknown 
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Nature of Study 
I used a quantitative cross-sectional study to determine if there was a difference in 
the survival of cervical cancer among women of different race after radiation therapy. I 
chose the quantitative methodology for this study. The quantitative method includes post 
positivist knowledge that provides part of the truth by observing numerical data from a 
large sample size, and making inferences from the samples (Isaza-Restrepo, Carvajal, & 
Montoya, 2016).  
The study was a cross-sectional study of secondary data obtained from 
Surveillance, Epidemiology, and End Results (SEER) dataset from 1973 to 2012. The 
analysis required using modes that included descriptive statistics, and a logistic regression 
analysis. I did not employ survival analysis. Survival analysis involves assumptions and 
extrapolations in the calculation to predict time to an event when researchers know that 
time is not sufficient to follow every participant to the end of life, and the cause of death 
could differ from the study events or predictors (Gassama, Bénichou, Dartois, & Thiébaut, 
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2017; Williams, Lewsey, Mackay, & Briggs, 2016). I employed a logistic regression 
analysis, which is the best method to describe the relationship between the dependent 
variable and the independent variables (Pourghasemi, Moradi, & Aghda, 2013) because the 
hypotheses do not address time to the event.  
These data from SEER were appropriate for use in the study because the SEER is a 
reliable source of information when conducting national studies based on delay adjusted, 
long term, and population-based incidence and mortality data (Siegel, Miller, & Jemal, 
2015). The SEER includes proper documentation of women with or without radiation and 
outcomes from follow up. The independent variables were the effect of early cervical 
cancer screening using radiation therapy among Non-Hispanic Blacks, Non-Hispanic 
Whites, Asians, and Hispanics, broken down by age and race groups. 
 Definition of Terms 
The independent variables were the effect of early cervical cancer screening using 
radiation therapy among non-Hispanic Blacks, non-Hispanic Whites, Hispanics, and 
Asians, and the effect of early cervical cancer screening using radiation therapy among age 
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groups. The dependent variable was the survival rates among races. These are the 
definitions of these variable terms:  
Cervical cancer: The malignancy of the cervical epithelium, which is the result of 
infection by HPV on the cervix (Maguire et al., 2015).  
Cervical intraepithelial neoplasia (CIN): CIN is the premalignant lesion with three 
histological stages: CIN1, CIN2, and CIN3 (Santesso et al., 2015). 
Cervical cancer survival: Is the prognostic value in cervical cancer. However, this 
value remains unclear (Pan et al., 2015). 
Cytology-based screening: The use of Papanicolaou (Pap) smear to examine the 
changes in the cervical epithelial cells for infections due to HPV (Subramanian et al., 
2016). The results of Pap tests are either low-grade Squamous intraepithelial lesion (LSIL), 
atypical squamous cells, or high-grade squamous intraepithelial lesion (Chengquan et al. 
(2015; Thrall, Janssen, & Mody, 2015).   
Human papilloma virus (HPV) Genotype 16, 18): The cause of cervical cancer, 
detected by Papanicolaou (Pap). The test shows either high-grade squamous intraepithelial 
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lesion (HSIL) or low-grade squamous intraepithelial lesion (LSIL; Barron, Austin, Li, & 
Zhao, 2015; Skinner et al., 2015).   
Race: The occurrence of names of people in the U. S. Census data more than 100 
times, and the address geocoded based on the longitude and, latitude from U. S. 2000 
Census book (Grundmeier et al., 2015; Rio & Alonso-Villar, 2015).  
Radiation: The transmission and emission of charged particles for the killing of a 
cervical cancer cell with minimal or no damage to the normal cervical epithelial cells 
(Kaur, Avasthi, Pujari, & Sarma, 2013).  
Radiation therapy: The delivery of doses in required amount for 5 to 6 weeks to 
maximize damage to the malignant cervical cancer cells and cause no damage to the 
surrounding normal cells (Ghose et al., 2015).  
Screening: A process of investigating a disease causation organism in an 
asymptomatic individual (Bulliard et al., 2014). Screening could opportunistic or 
organized; organized screening occurs when participants from a given population undergo 
a form of investigation to detect the presence of a disease-causing agent, or opportunistic 
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occurs when an individual undergoes screening outside an organized screening method 
(Bulliard et al., 2014).  
Staging: The use of surgical specimen obtained from a tissue such as a cervix to 
classify the patient as high, an intermediate or low risk for cervical cancer (Juan et al., 
2015; Matsuo et al., 2015). Early cervical cancer is Stage 1-11A (cancer is localized or 
regional), the late Stage is 11B-1VB (cancer metastasized), A is the absence of lymph 
nodes metastasis, and B is the presence of lymph nodes metastasis (Min Sun et al., 2015; 
Winer et al. (2015).  
Survival rate: Survival rate is x years for individuals with cancer who are alive for x 
years divided by the number of individuals diagnosed with same cancer for an x period of 
years within the study population (Wegwarth, Gaissmaier, & Gigerenzer, 2011). 
Testing: The detection of disease-causing agents before the symptoms become 
apparent, and early detection programs use public health instruments to detect individuals 
with cancer before the disease becomes advanced; subsequent treatment fails to achieve the 
desired outcomes (Bill-Axelson et al., 2014; Rajaraman et al., 2015). Saraiya et al. (2014) 
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stated that early testing is a preventive service supported by Affordable Care Act (ACA) 
for women with high risks of contracting HPV.   
Assumptions 
I assumed that the secondary data collected from SEER were reliable and could 
generalize the cervical cancer statistical data obtained if collected by any other agencies. 
 Scope and Delimitations 
I examined the secondary data from the SEER database for women who used or did 
not use radiation for early cervical cancer. The delimitation of the study was to participants 
living in United States; the result may not be generalizable to countries beyond United 
States. 
Limitations 
This study does not apply to women who developed early cervical cancer from in-
utero exposure to diethylstilbestrol; organ transplant; or the use of chemotherapy, such as 
chronic use of corticosteroid. I did not identify which HPV types were in the secondary 
data. The secondary data collected from SEER could not assume a causal role because the 
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data were not primary data, and they could only measure associations between independent 
and dependent variables.  
 Significance 
Professionals who examine and treat women with early cervical cancer in the 
United States can use the result of this study. The results of the study would contribute to 
the prognostic factors of survival for women of different races and age groups. The 
findings may motivate women to seek screening and treatment for early cervical cancer 
cases. This study may be a source of health education for non-Hispanic Blacks, White non-
Hispanics, Hispanics, and Asians to correct any misperception about early screening for 
cervical cancer, radiation therapy, and similar survival rates.  
The results of the study will add to the body of knowledge in epidemiology for 
understanding the effects of radiation for treating early stage cervical cancer for non-
Hispanic Black, White non-Hispanics, Hispanics, and Asians living in the United States. 
The outcomes of the study will contribute to social change by providing evidence for 
women for getting regular Papanicolaou test (Pap smear) and cervical cytology tests early 
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in life. The results of the study could contribute to positive social change if early detection 
of cervical cancer proves to reduce mortality among women who otherwise succumb to the 
disease. The results may help to keep families together and provide a better quality of life 
for women who receive early testing and radiation therapy.  
Summary 
Pimenta et al., (2013) stated that survival rates among women with cervical cancer 
is below average. Cervical cancer is the third most common cancer after lung and breast 
cancers in United States, despite the availability of tools for testing and making a diagnosis 
(Pimenta et al., 2013). Improvement in cervical cancer treatment due to age and the race is 
not clear, and no scholars demonstrated the association between radiation therapies, early 
testing, age, race, and survival rate (Zeng et al., 2015). Ellinor et al. (2015) argued that 
epidemiologists and physicians have the responsibility to pass correct information about the 
benefits of treatment to women to encourage them to participate in cervical cancer 
screening and treatment. Robinson et al. (2015) believed that survival of women with 
31 
 
 
 
cervical cancer depends on their awareness and participation in screening as well as 
treatment options.    
This chapter included the background, problem statement, purpose of the study, 
research questions, and hypothesis. The chapter also included discussion on the theoretical 
for the study, the significance of this study, and the implications for positive social change. 
In chapter 2, I explained the review of the literature on cervical cancer and the 
spatiotemporal relationship associated with the epidemiological triad. 
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Chapter 2: Literature review 
Introduction 
 Participation by women in early screening for cervical cancer is poor, and survival 
rate of women from cervical cancer treatment due to age, sex, and race is not clear (Torre et 
al., 2015). The purpose of this study is to examine the effects of radiation therapy on early 
cervical cancer detection based on age by group and race for women living in the United 
States. There are benefits to women understanding the advantages of getting early cervical 
cancer screening (Huh et al., 2015). One advantage of early screening is the opportunity to 
use the most effective treatment options to increase cancer remission. Radiation therapy 
kills malignant cervical cells while sparing the healthy cervical cells. There are no studies 
on the effects of radiation treatment for curing cervical cancer in an early stage status 
among different races or age by groups living in the United States (Östensson et al., 2015).  
In this chapter, I discuss the current literature findings related to my study. My 
discussion on the strategy to find current literature for the study includes a review of the 
epidemiological triad that is the theoretical framework I used for this research. Also, I 
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discuss research findings on cervical cancer survival based on various treatment options 
about the epidemiological triad.  
Literature Review Strategy 
I conducted an online search of relevant articles and journals using multiple 
databases such as Medline, Thoreau, Google Scholar, PsycINFO, ProQuest Central, 
Academic search Premier, ProQuest Health, EBSCO, Science and Ovid journals. Also, I 
searched the dissertations and theses database available through ProQuest to find empirical 
studies related to the treatment of cervical cancer. Other health science collections such as 
Medical Complete, Social science Journals, and Cochrane database of systematic review 
provided findings related to the epidemiological triad that was foundational for the study.  
I conducted searches using keywords, subject terms, and Boolean phrases. Some 
key search terms centered on cervical cancer, cancer, cervical, age, race, early detection, 
HPV testing, Papanicolaou (Pap) test, epidemiological triad, epidemiological triangle, and 
epidemiological model. The primary research period was within the last 5 years of 
publication for a majority of studies; however, researching beyond a 5-year period was 
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necessary to understand the background of the study phenomenon and a history of 
treatment used in cervical cancer treatment.  
Epidemiological Triad Theory 
Introduction 
The epidemiological triad was the theoretical framework for the study. Clark 
created the epidemiological triad in 1954 (Cohen & Shang 2015). The purpose of the triad 
was to study the relationship between an agent such as a procedure drug (early HPV 
testing), a host such as a person or community (women), and an environment such as the 
exposure to disease (risk of cervical cancer and radiation therapy) in disease transmission 
(Chaney & Rojas-Guyler, 2015). Hagan (2011) found that agent is efficient in disease 
transmission into the host, and is stable in the environment. Hagan demonstrated that the 
epidemiological triad was effective for understanding the interaction between the cycle of 
transmission of other diseases such as early HPV testing of women exposed to cervical 
cancer, and the rate of survival. 
35 
 
 
 
 Bunnik et al. (2014) argued that when controlling infectious agents, scholars must 
focus on the time between the distant exposure, the infection event, and the delay in the 
onset of transmission. Further, Bunnik et al. argued that infectivity depends on the distance 
between the host and the pathogen decay (virulence) rate; therefore, control is necessary 
because of the interplay of the infectious agent and infectivity in the environment. Rohrer 
et al., (2013) explained that the epidemiological triad provided a guide to quality 
assessment. When the research involved an epidemiological study that required testing 
associations between variables, researchers located variations on the environment (place), 
host (person), and time (procedure). I present a detailed description of the inter-
relationships in the epidemiological triad in the next section.  
Agent, Host, and Environment 
 Agent (procedure). The agent part of the triad includes chemical contaminants and 
mechanical forces that form an interaction between the host and an environment, resulting 
in the metamorphosis of a disease (CDC, 2012). Rohrer et al. (2013) applied an agent to 
time as in a pre and post intervention period or early and late testing period. Morabia 
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(2014) examined the concept of time in the epidemiological triad and argued that individual 
or groups of individuals enter and leave a population over time, and individuals develop 
varying health outcomes over time. Chaney and Rojas-Guyler (2015) referred to the agent 
as a procedure or drug such as HPV testing procedure. For this study, the time represented 
the difference between early period and late period testing using the HPV procedure among 
women. Blennow et al. (2015) explained that early testing is preferable to late testing for 
making a diagnosis of Alzheimer’s disease (AD) because early testing allowed for easy 
monitoring and prevention of a severe form of the disease.  
Early testing for biomarkers in the cerebrospinal fluid of people with mild cognitive 
impairment revealed peptide, amyloid-β, phosphorylated tau, and total tau prevented 
progression to AD and offered early treatment strategies (Blennow, 2015). Early testing for 
the Human Epidermal Growth Factor Receptor 2 gene or ERBB2 offered better care and 
prevented progression to full-blown breast cancer Stage IV (Wolff et al., 2014). Wolff et al. 
(2014) argued that the HER 2 gene expressed more than 15% to 20% in primary breast 
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cancers, and detection from early rather than late testing led to better management and 
increased the quality of care.  
Time related to early testing of a disease influences outcomes. Early testing 
provides increased success in disease detection and management that result in the cure and 
eradication of many diseases. The time element of the triad provides a necessary basis for 
comparing the effectiveness of early testing of cervical cancer compared to late testing 
among women when using radiation therapy for increasing the survival rates of women.  
Host (person). The host is a link in the chain of disease transmission between the 
agent and the manifestation of the disease. Hosts are humans, animals, or organisms 
harboring diseases leading to sicknesses (CDC, 2012). Females with HPV infect males 
during unprotected sex, causing males to contract the HPV; these infected males, in turn, 
infect other females during unprotected sex, causing the disease to spread (Liu et al., 2015). 
The disease originates in either males or females (Liu et al., 2015). According to the CDC 
(2012) report, a host was not always aware of harboring a disease such as men who carry 
the HPV.  
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The mechanism of action of the HPV that cause cervical cancer in the host remains 
unclear. Natarajase, Enthumathi, Shanmughap, Sumathi, and Das (2015) stated that 
infection of the cervix by HPV abolished the innate immune response by reducing the Toll-
like receptors-2 and TLR 4 expressions (pathogen recognition receptors) in cervical 
squamous cells. This reaction is the first carcinogenic event in cervical cancer 
development.  
The host demonstrates strong resistance to HPV infection. Paaso et al. (2015) 
reported that persistent HPV infection reduces cell-mediated immunity, and the women’s 
ability to survive the cervical cancer development depends on the level of CD4+ and CD8+ 
HPV-specific T-cell response that promote innate immunity against HPV 16 E2 protein and 
help apoptosis (programmed cell death). Researchers have reported that men could serve as 
a host to HPV. Pask and Rawlins (2016) reported that HPV could infect men from women 
leading to the development of genital warts, anal cancer and oropharyngeal cancers (throat 
cancer).     
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 Other disease processes involve host to produce diseases. Abdizadeh, Maraghi, 
Ghadiri, Tavalla and Shojaee (2015) reported that toxoplasmosis is an infection caused by 
Toxoplasma Gondi in nonimmune human beings and non-immune pregnant women as 
host, causing abortion and stillbirth. Early detection would be of advantage to prevent the 
harmful effects of the disease on the host (women and the pregnancy; Abdizadeh et al., 
2015). However, in the late stage of the disease, there would be parasites in the tissues, 
which makes it difficult to treat with drugs; patients (host) are less likely to tolerate the 
drugs. The development of HIV and Hepatitis C virus infection in human beings are 
examples of other ways hosts play roles in the transmission of diseases (Miao, Li, Zheng, 
Cohen & Liu, 2016).       
Environment (exposure). The environment is the place, geographical location, or 
exposure to the agent (Rohrer et al., 2013). Table 2 shows that there must be an 
environment for sexual intercourse, and the agents are unprotected sex among the females 
of all races and ages (the host). The outcome of this interaction is an exposure of the host to 
cervical cancer. Unprotected sex, oral sex, frequent change of partners without the use of a 
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condom, and development of sexually transmitted infection expose females to HPV 
(Knight, Needham, Ward & Roberts, 2016). Mullins, Widdice, Rosenthal, Zimet and Kahn 
(2015) argued that females tend to contract cervical cancer due to inconsistent knowledge 
about their safety following HPV vaccination, HPV and their perception of the risks of 
Sexually transmitted infections. Mullins et al. argued that inability of mothers to provide 
necessary HPV information to their daughters, and lack of information from providers for 
females during hospital visits encourages unprotected sex and late HPV testing.  
  
Table 2 
 HPV Virus Infection as it affects Agent, Host, and the Environment. 
 Environment 
 
Agent Host  Outcome 
Contracting 
HPV 
Sexual 
intercourse 
Unprotected 
sex 
Females 
and Males 
All ages 
All races  
Known 
(Exposure to cervical cancer  
among females) 
Treatment 
(Cervical 
Cancer) 
Early 
detection 
(within three 
Radiation 
therapy  
 
Females  
All ages 
All races 
Unknown 
Unknown 
Unknown 
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years of first 
sexual 
unprotected 
intercourse 
or by age 21 
unless there 
is sexual 
abstinence)  
 
Surgery with 
Radiation 
Therapy 
 
Females  
All ages 
All races 
 
Unknown 
Unknown 
Unknown 
 
Surgery 
without 
radiation 
therapy 
 
Females  
All ages 
All races 
 
Unknown 
Unknown 
Unknown 
Treatment 
(Cervical 
Cancer) 
Late 
detection 
(Anytime) 
Radiation 
therapy  
Females  
All ages 
All races  
Low  Survival 
Low  Survival 
Low  Survival 
 
Surgery with 
Radiation 
Therapy 
 
Females  
All ages 
All races 
 
Low  Survival 
Low  Survival 
Low  Survival 
 
Surgery 
without 
radiation 
therapy 
 
Females  
All ages 
All races 
 
Low  Survival 
Low  Survival 
Low  Survival 
 
Torre et al. (2015) argued that the HPV vaccination does not protect against 
established HPV infections and HPV genotypes that cause cervical cancer. Researchers do 
not know the outcome when females of all races and ages opt for early detection of cervical 
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cancer and receive radiation therapy, surgery with radiation therapy or surgery without 
radiation therapy (Östensson et al., 2015). When females of all races and ages with cervical 
cancer opt for late detection of the disease, the disease metastasizes to a different part of the 
body, the treatment modalities are not effective and the outcomes are a low survival from 
the disease. Jolly, Bessler, Ncube, Bey and Knight (2015) argued that some factors are 
responsible for the late detection of cervical cancer by females of all ages and races. These 
include inadequate knowledge of cervical cancer, low socioeconomic (SES) factors, lack of 
access to testing facilities, pain from tests such as colposcopy, and fear and embarrassment 
of having a positive cervical cancer diagnosis (Jolly et al., 2015).  
Spatiotemporal Relationship and Spread of Diseases 
Time, place, and person are constructs that explain the spatiotemporal relationship 
in cervical cancer spread from early to late spread. Hautala and Jauhiainen (2014) reported 
that spatiotemporal relationship is a process of building ideas from what other people have 
known based on time, place, and person, and this relates to the disease creation in spatial 
and temporal dimensions. Hautala and Jauhiainen believed that knowledge creation is an 
43 
 
 
 
interactive process that comes from people, agent and their environment as they process the 
thoughts and actions of another individual, and relate them to time (the past, present, 
future), and space. Hautala and Jauhiainen explained that time is linear and connected to 
space on a geographical surface, and space is surrounding the place.  
The model of spatiotemporal relationship explains the process of the spread of the 
cervical cancer. Lai et al. (2015) reported that past researchers had explained the spread of 
diseases based on the characteristics and activities of agents, host, and environment causing 
the disease; however, it is preferable to express the spread of diseases using spatiotemporal 
means within the epidemiological triad. This model uses a temporal and spatial approach to 
identify the flow of diseases (Lai et al., 2015). The triad uses time (the time the disease is 
detected), the person (the host such as women, race, and their ages), and place (where 
exposure takes place such as exposure to cervical cancer, and exposure to radiation 
therapy; Lai et al., 2015). There is a lack of information on the benefits of receiving 
radiation therapy early to prevent precancerous cervical lesions from becoming invasive 
lesions (Östensson et al., 2015). 
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A spatiotemporal understanding of disease spread led to an understanding of how to 
stop the spread of diseases. Lai et al. (2015) argued that a spatiotemporal approach 
examines the effect of continuous testing to prevent disease progression, and it offers early 
warning sign in disease surveillance. Also, the spatiotemporal model is useful for health 
care policy makers to formulate policies that may allocate more resources to areas of the 
communities to minimize the spread of a particular disease (Lai et al., 2015).  
 Cervical Cancer 
HPV 
The rate of exposure to HPV remains high. In the United States, over 80 million 
females alone host the HPV, while 14 million new infections occurred annually (Kenya et 
al., 2015). Wright et al. (2015) found that the HPV had different strains (6, 11, 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, and 66).  The strains that were most effective for 
mutating into cervical cancer were the Genotypes 16 and 18 (Wright et al., 2015). Although 
contracting HPV Genotypes 16 and 18 lead to squamous intraepithelial lesions (dysplasia), 
a small percentage of the dysplasia produces cervical cancer cells in women (Trimble et al., 
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2015). Kenya et al. (2015) argued that other HPV genotypes did not result in the cervical 
cancer disease among women.  
Risk Factors for Contracting HPV 
There are factors that increase the spread of the HPV virus among women. Men are 
the original carriers of HPV, and unprotected sex with HPV-infected men is a risk factor 
for women to contract HPV (Vermandere, Naanyu, Degomme & Michielsen, 2015). 
Factors that spread the HPV infection include men with many sexual partners having 
unprotected sex, and women with many sexual partners having unprotected sex with HPV-
infected men. This pattern continues with HPV-infected women infecting other men, who 
in turn infect other women (Bezabih, Tessema, Sengi, & Deribew, 2015; Nayak, 2015). A 
single exposure to HPV among women who have unprotected sex with HPV-infected men 
to result in HPV infection, but the single exposure does not necessarily lead to the 
development of cervical cancer (Cooper & Gordon, 2015).  
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Behaviors Associated with Cervical Cancer after HPV Exposure 
 There are behaviors that increase the risk of the HPV (16 and 18 genotypes) 
infection mutating into cervical cancer. Nayak (2015) stated that prolonged use of 
contraceptives, HIV infection, multiparity, and promiscuity were factors associated with 
HPV mutating into cervical cancer. Chung (2015) explained that long-term use of 
contraceptives increased the risk of developing cervical cancer in HPV-infected women by 
stimulating estrogen and progesterone receptors that trigger cervical cancer development. 
Chung indicated that the inverse is also true, which is that a reduction in contraceptives had 
a positive relationship with the risk of developing cervical cancer. Parham et al. (2015) 
stated that women infected with HIV were at increased risk of the HPV infection mutating 
into cervical cancer. 
 An HIV diagnosis increased the risk of contracting HPV infection by reducing the 
host’s immunity and the ability to fight against the development of HPV. Smoking also 
increased the risk of the HPV virus developing into cervical cancer (Wieland et al., 2015). 
Smoking increases the HPV load in the cervical epithelium. The HPV-positive women who 
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smoked had an increased level of HPV 16 and 18 DNA loads (Wieland et al., 2015). The 
increased HPV loads damaged the epithelium, causing CIN that  developed into cervical 
cancer (Wieland et al., 2015).  
Early HPV Screening 
Testing women for HPV are easy to do and cost effective; however, O'Connor et al. 
(2014) found that testing led to psychological and emotional anxiety and stress among 
women. O'Connor et al. argued that some women believed the HPV infection was a 
sexually transmitted disease, and therefore a positive result would cause other people to 
believe the women lived a life of promiscuity, this perception would result in social 
shaming.  
Women often worry about the outcome of screening. Smith (2014) explained that 
early screening using Pap and HPV screening, though, prevent the pre-cancer stage from 
developing into invasive cancer following treatment of the positive cases, but women with 
high-risk HPV positive or abnormal Pap test usually develop psychological problems 
because of the fear of developing cervical cancer. Smith explained that abnormal Pap test 
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or HPV DNA positive test could lead to more screening using Colposcopy or biopsy, which 
may increase fears of these additional tests. Health caregivers must explain the benefit of 
early testing to patients, that both tests are important when carried out early to reduce the 
advancement of persistent infections with HPV virus (Smith, 2014).  
The United States is not an exception in the global persistence of cervical cancer. 
Wang et al. (2014) reported that the incidence of cervical cancer was on the rise among 
younger women in the United States with poor clinical outcomes, despite the knowledge, 
prevention, and treatment modalities for the causative organism. Fleming, Schluterman, 
Tracy, and Temkin (2014) argued that there was unequal treatment after early detection of 
cervical cancer. Some women received radiation; others received surgery, and there was no 
data on the control variables such as a race on radiation therapy. 
Researchers have shown that age is important in the management of cervical cancer. 
Smith et al. (2015) reported that age was important in the development of the disease, and 
the screening procedures were Pap smear test and HPV DNA tests for women from ages 21 
to 65 years. Saslow et al. (2012) argued that screening must start at age 21 and those 
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women at ages 21-29 years must receive screening every three years using a Pap test. 
Women that were 30-65 years must screen for HPV using the Pap smear and HPV DNA 
tests every five years. Some women must screen every three years using the Pap smear test 
alone (Park et al., 2015). Screening should continue for 20 years after the treatment for 
CIN2, CIN3, and adenocarcinoma in situ (Saslow et al., 2012).  
Some exceptions to cervical cancer screening occur. Exceptions include women 
with two consecutive negative Pap and HPV tests within the last ten years or women who 
had a hysterectomy (Saslow et al., 2012). Also, Smith et al. stated that the criteria for an 
exception were for women older than 65 years of age and women with three consecutive 
negative Pap smear tests. These women did not need screening for the HPV and cervical 
cancer. Researchers had argued that SES is an important factor in determining when some 
women were likely to engage cervical cancer screening (Tervonen et al., 2016).    
Early Screening vs. Late Screening 
Researchers demonstrated that early testing for cervical cancer could speed up the 
treatment of cervical cancer, and late HPV testing worsened the diagnosis. 
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Sankaranarayanan (2014) stated that HPV testing offered early detection of precancerous 
lesions of the cervix, and cancerous lesions if women present late. Benard et al. (2014) 
reported that early HPV and Pap tests are useful to determine the health status of a woman 
before or during HPV infection and the development of cervical cancer and are the sources 
of education for women concerning the disease. Benard et al. stated that the HPV and Pap 
tests provide evidence-based screening practices for cervical cancer, and help to prevent the 
precancerous lesions from progressing to invasive cervical cancer.  
Persistent infections of the HPV virus led to the development of cervical cancer. 
Hariri, et al. (2015) explained that researchers developed emerging infections program 
(EIP) for Cervical Intraepithelial Neoplasia (CIN 1, 2, 3) to screen women from age 
28years for persistent infections of HPV. Hariri et al. reported that researchers should focus 
on the environment or the place of the high risk of HPV infection as catchment areas for 
screening HPV genotypes 16 and 18, the most virulent of HPV for cervical cancer.  
Early testing detects precancerous lesions. Perkins and Stier (2014) explained that 
HPV testing has increased sensitivity than Pap test and that HPV test detects 95% of HPV 
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while Pap test detects about 40-70% of HPV, when the physicians asked for the two tests, 
the detection rate increased above 95%. Perkins and Stier stated that early HPV and Pap 
tests detect precancerous lesions before progression to invasive lesions detected by late 
HPV testing, and early HPV and Pap tests reduce the incidence by 50%. The risk of 
developing cervical cancer or cervical dysplasia after three years of negative Pap test is 
.78%, after three years of negative HPV test is .34% and after three years for both Pap and 
HPV tests is .30% (Perkins & Stier, 2014). Women with late testing and women missing 
their testing dates will progress to cancerous lesions if there are preexisting precancerous 
lesions (Perkins & Stier, 2014).  
 Cervical Cancer Screening and SES 
The association between cervical survival and SES is inconsistent and inconclusive 
despite reports that SES contributes to health disparities (Lin, Shootman & Zhan, 2014). 
Williams, Moneyham, Kempf, Chamot and Scarinci (2015) argued that cervical cancer 
rates were higher in resource-constraint regions due to the inability of women to adhere to 
screening recommendations. Tay et al. (2015) argued that women with low employment 
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status belong to the low socioeconomic class, and were less likely to undergo cervical 
cancer screening or complete the recommended number of screenings. Tervonen et al. 
(2016) argued further that there is an association between lower SES and advanced stage of 
cancer in the United States. Tervonen et al. explained that the strength of association 
depends on the health care system because researchers observed differences in countries 
with high levels of health equity such as Finland. The United States study revealed that 
socioeconomic disadvantages led to increased risk of late stage cancers such as colorectal, 
prostate, and breast cancers (Tervonen et al., 2016). 
Diagnosis of Cervical Cancer 
The reports of HPV and cervical cancer continue to grow globally. Kjær, Munk, 
Junge, and Iftner (2014) explained that 500,000 women were diagnosed with cervical 
cancer every year, while 270,000 (54%) of women died from the disease. Kjær et al. (2014) 
argued that the HPV virus was responsible for the development of high-grade cervical 
lesions (HSIL) in women and was further responsible for cancer development in men. Kjær 
et al. argued that HSILs caused cancers in the anus, vagina, penis, oropharynx, and vulva 
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respectively among males and females. The HPV infection was associated with 5 percent 
of all cancers diagnosed globally (Kjær et al., 2014).    
Identifying the histology of cervical cancer cells types is useful when detecting the 
growth and spread of cancer cells in women. Lazzari et al. (2014) described cervical cancer 
as having three histological types that are Adenocarcinoma, Squamous cell carcinoma, and 
Adenosquamous. Clinicians use examinations and image techniques such as magnetic 
resonance imaging (MRI), and Computed Tomography (CT) when diagnosing cervical 
cancer. Lazzari et al. argued that the MRI was the best imaging technique for identifying 
the location, size, and metastasis of cervical cancer, with 88% to 97% sensitivity, and 93% 
specificity. Driscoll, Halpenny, Johnston, Sheehy, and Keogan (2015) explained that there 
were four stages of cervical cancer and three methods of diagnosing each stage; the three 
methods for diagnosing each stage of cancer involve surgical, clinical, or radiological 
methods. Table 3 explains the four stages of cervical cancer spread in women detected in 
Stages Ia to IIa and the possibility of getting surgery and radiation.  
Table 3  
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Stages in Cervical Cancer Diagnosis 
Stage at 
diagnosis 
Interpretation 
of stages 
  Treatment Outcome/risk Unknown 
I  
  
Tumor limited to the cervix 
Ia 
  
Lesion less 
than 5 cm 
Surgery only, 
Radiation, 
Surgery + 
Radiation 
 
Removal of 
tumor with 
surgery, radiation 
kills cervical 
cancer cells 
Whether all cancer 
cells are removed 
with surgery, the 
benefits of radiation 
therapy 
Ib 
  
Lesion greater 
than 5 cm  
Surgery only, 
Radiation, 
Surgery + 
Radiation 
 
Removal of 
tumor with 
surgery, radiation 
kills cervical 
cancer cells   
Whether all cancer 
cells are removed 
with surgery, the 
benefits of radiation 
therapy   
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II 
 
Tumor extends past the cervix to lower part of the uterus 
IIa 
 
No lymph 
nodes 
involvement 
Surgery only, 
Radiation, 
Surgery + 
Radiation 
  
Removal of 
tumor with 
surgery, radiation 
kills cervical 
cancer cells  
Whether all cancer 
cells are removed 
with surgery, the 
benefits of radiation 
therapy  
IIb 
 
lymph nodes 
involvement  
Surgery and 
chemotherapy 
The beginning of 
metastasis, 
surgery, radiation 
not effective. 
Chemotherapy 
might be 
effective. Out of 
the scope of this 
We do not know the 
extent of spread of 
cervical cancer cells. 
Out of the scope of 
this proposed study. 
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proposed study 
 
III 
 
Tumor invades abdominal tissues, not beyond the diaphragm 
IIIa 
 
Tumor 
restricted to 
one site e.g. 
uterus and 
ovary 
Chemotherapy Surgery, radiation 
not effective. 
Chemotherapy 
might be 
effective. Out of 
the scope of this 
proposed study 
We do not know the 
extent of spread of 
cervical cancer cells. 
Out of the scope of 
this proposed study.  
IIIb 
 
Tumor 
restricted to 
multiple sites  
Chemotherapy Surgery, radiation 
not effective. 
Chemotherapy 
might be 
We do not know the 
extent of spread of 
cervical cancer cells. 
Out of the scope of 
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effective. Out of 
the scope of this 
proposed study 
  
this proposed study.  
IV 
 
Metastasis to pelvic regions, beyond diaphragm, and para-aortic lymph 
nodes  
Iva 
 
Tumor cells 
found in the 
rectum and 
bladder 
Chemotherapy Surgery, radiation 
not effective. 
Chemotherapy 
might be 
effective. Out of 
the scope of this 
proposed study 
We do not know the 
extent of spread of 
cervical cancer cells. 
Out of the scope of 
this proposed study. 
IVb 
 
Tumor with Chemotherapy Surgery, radiation We do not know the 
58 
 
 
 
distant 
metastasis 
not effective. 
Chemotherapy 
might be 
effective. Out of 
the scope of this 
proposed study 
extent of spread of 
cervical cancer cells. 
Out of the scope of 
this proposed study.  
  
These methods aid in determining whether cancer metastasized from one stage to 
the next, with stage one being the first stage and stage four the last stage of cervical cancer, 
reflecting the occurrence of ultimate metastasis (Prat & Mbani, 2015). Failure to diagnose 
cervical cancer early usually resulted in metastasis to different parts of the body including 
the lymph nodes (pelvic and Para-aortic), which in turn results in early mortality (Prat & 
Mbani, 2015). The following discussions are on the treatments used in cervical cancer 
patients. 
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Treatment of cervical cancer 
In recent years, patients who experienced early cervical cancer detection benefitted 
from using radiotherapy with chemotherapy or radiotherapy without chemotherapy, which 
was the primary treatment option for increasing survival rates among women (Lazzari et 
al., 2014). Treatment modalities and the availability of equipment for diagnosis were of 
great importance when managing cervical cancer.  
Participation in screening for cervical cancer among women in developed countries 
was not as high as possible. Researchers believed that 42% of women in the United States 
do not engage in early screening (Cohen et al., 2016). Cohen et al. argued that the 
screening rates among women varied by region in the United States and by age. The 
researchers indicated that 44% to 81% of women between ages 45 years to 64 years 
engaged early screening. Approximately 67% of the women did not engage the U.S. 
screening recommendations, indicating a high level of non-adherence among U.S. women, 
even though there was awareness among screening centers on a nationwide level (Cohen et 
al., 2016).  
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Despite the available knowledge of causative organisms of cervical cancer and 
effective treatment modalities, there remains inadequacy of awareness of the effectiveness 
of using radiation therapy among women of all races and ages that undergo early screening 
in the United States (Chen, Kessler, Mori, & Chauhan, 2012). Researchers have argued that 
there is a benefit from increasing the number of women that undergo early (under age 40) 
cervical cancer screening because these researchers have observed an increase in 
nulliparous women diagnosed with early cervical cancer ( Choi et al., 2015). The following 
are discussions on treatment options such as surgery, radiation, and treatment combinations 
for removing or curing cervical cancer for women with early stage diagnoses and late stage 
diagnoses. 
Treatment of early cervical cancer   
The treatment modalities for early cervical cancer are surgery and radiation. 
Treatment for cervical cancer is effective and lead to cure when detected early, and the 
prognosis of cervical cancer depends on the staging (Lau et al., 2015). Radiation therapy 
alone or in combination with another therapy has proofed increase survival in many 
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diseases such as lung, breast, and colorectal cancers (Landry et al., 2015). Researchers have 
noted the disparities in the outcomes of the use of radiation therapy for breast cancer 
among different age groups and races (Powers et al., 2015). There is a lack of information 
on the benefit of using radiation therapy in cervical cancer in early age groups and races 
and needs to be further studied (Fang et al., 2015).  
Surgery Treatment 
Early stage diagnosis. Surgery is one of the recommended treatment modalities for 
addressing early stage cervical cancer in women. Shazly, Murad, Dowdy, Gostout and 
Famuyide (2015) stated that the treatment for early cervical cancer is surgery such as 
radical vaginal hysterectomy (open, vaginal, abdominal, laparoscopic, or robotic), but there 
is a lack of evidence to support the effectiveness of surgery for early cervical cancer. Pareja 
et al. (2015) argued that surgeons used radical trachelectomy or cervicectomy (removal of 
cervix only to preserve fertility in young women that deserve to bear children). Pareja et al. 
stated that surgeon-recommended trachelectomy often leads to high recurrence rate. There 
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are no effective and conclusive policy recommendations for surgery in early stage cervical 
cancer (Pareja et al., 2015).  
Late stage diagnosis. Vizza et al. (2015) stated that surgeons used radical surgery 
for the tumors that are visible, but due to metastasis, most tumors are not visible; surgeons 
followed the surgeries with chemo-radiotherapy as treatment modalities for advanced 
cervical cancer. Surgery reduced the tumor size in late stage, but could not remove the 
obscured cervical cancer cells; however, the outcome of treating late cervical cancer with 
surgery remains uncertain (Vizza et al., 2015). Ramondetta et al. (2015) supported the idea 
that treating late stage cervical cancer with surgery, chemotherapy, and radiation therapy 
offered little or no significant outcomes.    
Radiation Therapy Treatment 
Early stage diagnosis. Treatment of early stage cervical cancer involves radiation 
therapy. Heijkoop et al. (2015) reported that Intensity Modulated Radiotherapy (IMRT) is 
the recommended treatment for early stage cervical cancer. The IMRT is better than the 
conventional 3-dimensional radiotherapy for effective sparing of the healthy tissues while 
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killing the cancer cells (Heijkoop et al., 2015). Fu et al. (2015) argued further that using 
radiation therapy before surgery shrinks the tumors and makes tumor removal by radical 
surgery easier to do. Fu et al. stated that currently, radiation therapy is a standard 
therapeutic approach for treating early cervical cancer.  
Late stage diagnosis. Radiation treatment for late stage offered no improvement in 
prognosis. Wakatsuki et al. (2015) reported that metastases occur at higher frequencies in 
late-stage cervical cancer, and when surgeons offered radiation therapy as the necessary 
treatment, the result is a poor outcome. Lutgens et al. (2016) argued that radiation therapy 
with cisplatin-based chemotherapy (RT-CT) is the standard therapeutic approach to 
advanced stage cervical cancer. Lutgens et al. argued further that the advantages of 
radiology in advanced stages were less obvious than in early stages.  
Surgery and Radiation Therapy Treatment 
Early stage diagnosis. Surgeons use surgery and radiation for better management 
of cervical cancer in the early stage of the disease. Sert et al. (2016) reported that surgery 
had intra-operative complications, which required postoperative radiation therapy. Winer et 
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al. (2015) stated that a combination of surgery and radiation therapy would increase 
survival in early stage of cervical cancer. However, the ratio of women that received 
radiotherapy to women who did not received radiotherapy was 1:2 (182 women received 
surgery, 98 women received radiotherapy) (Alexandre et al., 2017). 
Late stage diagnosis. Surgeons tend to treat the late stage of cervical cancer with 
combinations of surgery, radiation. Fournel et al. (2016) explained that advanced stage 
cervical cancer are unresectable, and surgeon often tried a combination of radiotherapy and 
surgery, however, the outcomes have never been proven successful. Abou-Taleb et al. 
(2016) argued that the physicians treated the late stage cervical cancer with a combination 
of surgery and radiation therapy to reduce the toxic effect of the disease. Abou-Taleb et al. 
did not specify the advantages and disadvantages of the treatments.  
Other Treatment Modalities 
Some women were using treatment methods for experiencing less stress that was 
free or cost little when compared to radiation and surgery treatments (Tang et al., 2015). 
There are other methods of treating cancers such as cancer immunotherapy (Regan, Guth, 
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Coy, & Dow, 2016). Coley’s treatment is a type of immunotherapy treatment used for 
treating patients with a late stage cervical cancer diagnosis (Eskander & Tewari, 2015). The 
treatment is a process of inducing fever from artificial viral infection leading to the 
development of leukocyte proliferation resulting in the body producing enzymes, hormones 
or chemicals that destroyed cancer cells (Dhama et al., 2015). Coley’s treatment has led to 
the development of Bacillus Calmette–Guerin vaccine (BCG) in the treatment of superficial 
bladder cancer and demonstrated cancer-protective effect when treating early stage disease 
(Bross et al., 2015). This mode of therapy needs further investigation.  
Some women would have embraced homeopathic treatment. Homeopathy is a 
science that embraces the belief that some preparations could facilitate self-cure by 
stimulating the body to eliminate waste and correct equilibrium (Dossett, Davis, Kaptchuk 
& Yeh, 2016). Mathie et al. (2016) searched for evidence of validity in using homeopathic 
treatment in disease management, and the conclusion was that none of the evidence was 
free of potential bias, and the result was either uncertain or inadequate. Available studies 
did not show support for homeopathic forms of treatment, indicating no scientific support 
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because of lacking information on effectiveness (Stub, Musial, Kristoffersen, Alræk, & 
Liu, 2016). In summary, conducting this proposed study, the treatment group consists of 
women with cervical cancer who received radiation therapy alone, or radiation with 
surgery, and the control group that consists of women with cervical cancer who received 
other treatments without radiation therapy. 
  Cancer Survival Rates 
Cervical cancer survival rates vary within racial groups. DeSantis, Ma, Bryan, and 
Jemal (2014) reported that survival rate in breast cancer was lowest in African-American 
with 78.9% compared to 88.6 in non-Hispanic Whites, 91.1% in Asian American/Pacific 
Islanders, and 87.0% in Hispanic/Latina. Yu et al. (2015) stated that survival rate in lung 
cancer following surgery in early detection when there is no metastasis is better, 
application of radiation in early and advanced lung cancer is not clear, and more research is 
needed to examine the benefits of using radiation therapy in lung cancer. Jansen, 
Hoffmeister, Arndt, Chang‐Claude, and Brenner (2014) stated that overall survival rate in 
colorectal cancer (CRC) in stages I to III was 18 months after diagnosis. However, the 
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CRC-specific survival following the use of B-blockers such as ß2-adrenergic (propranolol) 
was 17 months longer than overall survival. 
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Cervical cancer morbidity and mortality 
Women with late testing incurred advanced stage of cervical cancer from CIN. 
Nygard et al. (2014) reported that about 30 % of CIN 3 lesions would lead to cervical 
cancer if left untreated for 30 years. In women of childbearing age, the existence of CIN 3 
could lead to premature delivery, and it could affect the health of the newborn child. Miller, 
Hanson, Johnson, Royalty, and Richardson (2014) explained burden of the disease among 
women in the U. S., despite the preventive and treatment options that are available. The 
authors argued that despite the improvement in prevention and treatment, the burden of 
cervical cancer shows disparities based on race and SES.  
Methodological Critique of Epidemiological Studies  
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A summary of epidemiological studies in Table 4 provide examples of models used 
when analyzing cross-sectional quantitative studies. Henderson and Elsass (2015) stated 
that researchers used the cross-sectional study to explore psychological, demographical, 
and social predictors in research activities. Warwick, Falaschetti, Rockwood, Mitnitski, 
Thijs, Beckett, and Peters (2015) stated that cross-sectional study could be used to 
investigate survival following treatments, by demonstrating the effectiveness of 
hypertensive medications on hypertensive patients. The survivor causal effect (SCE) is the 
effect of treatments on the outcomes of the population that survived when given necessary 
treatment 
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 The sample size is important for effective use of statistical methods in the 
epidemiological study. Yanagihara, Wakaki and Fujikoshi (2015) reported that sample size 
(N) was important in planning a research study that involved statistical significance level, 
power, effect size, null and alternate hypothesis. A cross-sectional study has its defect in 
the choice of research design. Dall'Ora, Griffiths, Ball, Simon, and Aiken (2015) reported 
that cross-sectional study is limited in its ability to infer causality, but has a strong ability to 
infer associations between predictor variables and the outcome variable. 
 
Table 4 
Methodological critique of epidemiological study 
References Researc
h Design 
Measures Stat 
Model 
Sample 
size (N) 
Findings 
Proposed 
Study 
Quantitat
ive 
methodol
ogy, 
Cross-
sectional 
study  
Age by 
year, Race 
by 
ethnicity. 
Time to 
event, 
HPV 
Logistic 
regressio
n, Chi-
Square 
test of 
associatio
n  
206 There is a lack of 
information on the 
benefit of radiotherapy 
for women with early 
cervical cancer based on 
age and race. Study 
between1973 -2012, 
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Testing 
period 
(Early or 
late)  
 
 Treatment 
by level 
(radiation, 
surgery 
with 
radiation, 
no 
radiation) 
U.S. 
 
To be determined 
Diels et al., 
(2015)  
Cross-
sectional 
study 
Age, 
health-
related 
quality of 
life 
(HRQoL), 
treatment 
of prostate 
cancer 
(radiation, 
androgen, 
surgery, 
chemother
apy), cost  
Goodness 
of fit, 
median 
regressio
n model 
602 Prostate cancer is the 
most common cancer 
among men in Europe. 
The researchers 
conducted the study to 
examine the effect of 
treatments on prostate 
cancer. The research 
revealed that 
chemotherapy was the 
best treatment for 
prostate cancer.  
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Liang et al., 
(2016)  
Cross-
sectional 
study 
  
Age, 
Education, 
Income, 
Religion, 
Marital 
Status, 
Living 
status, 
Cancer 
stage, 
Time since 
diagnosis, 
Metastasis, 
Surgery 
Status   
 
Pearson 
correlatio
n, Linear 
regressio
n    
201 Researchers noted that 
women with breast 
cancers experienced 
distress at diagnosis. 
The study was to 
establish the distress in 
women with breast 
cancer and the scope of 
management. The 
researchers found that 
symptoms management 
self-efficacy acted as 
mediator between 
symptoms distress and 
quality of life (QoL) 
Guertin et 
al., (2015)  
Cross- 
sectional 
study  
Age, 
Gender, 
Race, 
Education, 
Smoking, 
Pack-
years, Age 
at smoking 
initiation, 
Prior lung 
cancer 
diagnosis 
  
Logistic 
regressio
n analysis  
6,108 Researchers stated that 
time to first cigarette 
(TTFC) after waking 
and nicotine 
dependence are 
associated. The study 
investigated the 
association between 
TTFC and chronic 
obstructive pulmonary 
disease (COPD). The 
study detected that 
shorter TTFC leads to 
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increased risk of COPD.  
  
Bregendahl
, 
Emmertsen
, 
Lindegaard 
and 
Laurberg 
(2015)  
Cross- 
sectional 
study  
Major 
LARS, 
Symptoms 
of sexual 
dysfunctio
n, 
symptoms 
of urinary 
dysfunctio
n 
Multiple 
logistic 
regressio
n  
516 Information concerning 
urinary and sexual 
dysfunction after rectal 
cancer treatment in 
women is limited. This 
study investigated the 
relationships between 
using radiotherapy, and 
surgery to the 
development of bowel 
dysfunction.  
Pazaitou-
Panayiotou, 
Panagiotou, 
Polyzos and 
Mantzoros 
(2015)  
 
Cross- 
sectional 
study 
Age, Sex, 
Tumor 
size, 
Histology, 
Stage, 
prechemot
herapy 
serum 
albumin, 
Logistic 
regressio
n model, 
t-test, 
Mann-
Whitney 
U test, 
Kaplan- 
Meier 
89 Treatment for curative 
esophagogastric cancer 
was chemotherapy, 
before surgery with 
narrow therapeutic 
index. The researchers 
investigated whether 
treatment with narrow 
therapeutic index affects 
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pre-
chemother
apy 
Neutrophil 
lymphocyt
e ratio, 
(Basal 
Metabolic 
Rate 
(BMI) 
test, Log-
rank test 
survival status. The 
researcher found out 
that adjuvant toxicity 
affected the long- term 
survival of patients with 
oesophagogastric cancer 
 
 Summary and Transition 
Cervical cancer on early testing in the United States could result in increased 
survival rates if surgeons consider radiation therapy as number one therapy or in 
combination with surgery. This chapter provides a review of the literature on surviving 
cervical cancer, contracting the disease, and the behaviors that increase a woman’s risk to 
contract cervical cancer. Torre et al. (2015) emphasized the importance of knowing 
survival rates of women with cervical cancer; however, Torre et al. also stated that there 
remains a deficiency of awareness on the survival rates due to age, race, and sex among 
women in the United States. This study uses epidemiological triad model. Bhopal (2012) 
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argued that epidemiological studies should make use of epidemiological models of time, 
place, and person molded from the agent, host, and environment models. This knowledge 
informed the use of an epidemiological triad of time, place, and person for the proposed 
study of early testing, radiation therapy, and survival rate in women with cervical cancer in 
the United States.  
In this chapter, I reviewed the constructs of an epidemiological triad with respect to 
time, place, and person. The knowledge of the spatiotemporal relationship of the constructs 
can assist in understanding how to interrupt the spread of the disease. In this chapter, I also 
presented information on early and late HPV screening by women in the United States, the 
criteria for making diagnoses based on the four stages of cervical cancer, and the treatment 
modalities for the four stages. The information regarding radiation therapy benefits in early 
stage cervical cancer is not clear and this lack of clarity might be responsible for the low 
participation of women in early cervical cancer screening programs (Östensson et al., 
2015). In this proposed study, I intend to focus on the benefits of early radiation therapy 
among women based on age groups and races.     
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In Chapter 3, I present the research design and the research questions for this 
proposed study. I justify the choice of design and methodology and discuss the statistics 
that I plan to use to address the research questions. Finally, I consider the potential internal 
and external validity of my results based on my research design. 
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Chapter 3: Results 
The purpose of this quantitative study was to analyze secondary data from the 
SEER between 1973, and 2012. Cervical cancer is preventable with early detection, but it is 
not preventable when the diagnosis progresses from early stage to late stage. Subramanian 
et al. (2016) stated that cervical cancer is preventable, and 70-80 % of women are screened 
for cervical cancer annually in United States. The unscreened 20-30% women remain 
significant, and researchers must encourage evidence-based cervical cancer screening to 
lower the incidence of the disease in United States. (Subramanian et al., 2016).  
Some women have experienced a recurrence of cervical cancer following surgery 
for removal of pre-cancerous lesions to prevent cervical cancer, but a few years later, the 
women experience an advanced stage of the disease due to recurrence. Abe et al. (2015) 
argued that recurrence due to surgical removal of cervical cancer has led to the introduction 
of radiation therapy in early cervical cancer. Legge et al. (2015) argued that despite 
advances in diagnosis and treatment, women with early-stage cervical cancer treated with 
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surgery only have 30-50% recurrence, and such women may die from the disease. The 5-
year prognosis from such recurrence is 3-13% (Legge et al., 2015). More cervical cancer 
cells remain in the normal tissues of the cervix that the surgeon could not remove during 
the surgery and they later develop into advanced stage cancer.  
In radiation therapy, radiation is applied at a dose that individual women can 
tolerate into both the cervical cancer cells and the surrounding normal tissues with the hope 
that the radiation will kill cancer cells and spare the normal tissues (Chang, Bezjak, 
Mornex, & IASLC Advanced Radiation Technology Committee, 2015). In pre-Obama 
care, some women could not afford health insurance, with Obama care, insurance gives 
women access to health care (Test & Block, 2013). Women’s lack of participation in early 
screening is due to psychological reason, as some women do not want to go screening, and 
women of some races are reluctant to go for screening (Vinekar et al., 2015).  
Lack of participation in screening varies among groups of women. Women of older 
ages tend to go for screening than women of younger ages (Alford et al., 2015). There is a 
lack of information on the benefits of radiation therapy for females based on ages and races 
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in the United States. The purpose of this study was to explain the effects of early radiation 
therapy among women with cervical cancer in United States. I used the SPSS software for 
statistical tests to perform descriptive statistics and logistic regression analysis.  
In this chapter, I discuss the research question for this study, research design, 
rationale, and how the design will contribute positively to the body of knowledge in the 
field of epidemiology. I used the setting and sample section to summarize and justify the 
sampling procedures, sample size, and the study population. This section includes the data 
analysis, the screening procedures, and the analytic methods. The last two sections address 
threats to internal and external validity; finally, I discuss the ethical procedures in accessing 
the secondary data from SEER, the summary, and transition to Chapter 4.    
Research Questions and Hypothesis 
In conducting this study, I gained an understanding of the association between 
radiation therapy and early cervical cancer detection among women in the United States 
based on age and race. There was a systematic analysis of secondary data collected from 
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different parts of United States by SEER made available to researchers for future studies. I 
used the following research questions:  
RQ1: What is the association between testing (early HPV VS late HPV) and 
survival rate of women when diagnosed with Stage IA to IIA cervica l cancer? 
Ho1: There is no association between testing (early HPV VS late HPV) and survival 
rate of women when diagnosed with Stage IA to IIA cervica l cancer? 
Ha1: There is an association between testing (early HPV VS late HPV) and survival 
rate of women when diagnosed with Stage IA to IIA cervica l cancer? 
RQ2: What is the association between age and survival rates of women when 
diagnosed with Stage I to IIa cervical cancer?  
Ho2: There is no association between age and survival rates of women when 
diagnosed with Stage I to IIa cervical cancer.  
Ha2: There is an association between age and survival rates of women when 
diagnosed with Stage I to IIa cervical cancer.  
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RQ3: What is the association between race and survival rates when diagnosed with 
Stage I to IIa cervical cancer? 
 H03: There is no association between race and survival rates when diagnosed with 
Stage I to IIa cervical cancer. 
  Ha3: There is an association between race and survival rates when diagnosed with 
Stage I to IIa cervical cancer.  
RQ4: What is the association between radiation therapy and survival rates of 
women when diagnosed with Stage I to IIa cervical cancer? 
H04: There is no association between radiation therapy and survival rates of women 
when diagnosed with Stage I to IIa cervical cancer. 
Ha4: There is an association between radiation therapy and survival rates of women 
when diagnosed with Stage I to IIa cervical cancer. 
 RQ5: What are the associations between five regions in the United States and 
survival rates of women when diagnosed with Stage I to IIa cervical cancer.  
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H05: There are no associations between five regions in the United States and 
survival rates of women when diagnosed with Stage I to IIa cervical cancer. 
Ha5: There are associations between five regions in the United States and survival 
rates of women when diagnosed with Stage I to IIa cervical cancer. 
This study was a quantitative, cross-sectional study using secondary data obtained 
from SEER, and I used the study participants to answer research questions as presented in 
Table 5. 
 Table 5 
Research Questions, Independent Variables, and Participants 
Research question           Independent variable                       Participants 
RQ 1                                  Early/Late HPV testing         Women diagnosed with 
cervical cancer  
RQ 2                     Age (20-29, 30-39, 40-49, 
>50  
Women diagnosed with 
cervical cancer  
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RQ 3 Race Women diagnosed with 
cervical cancer  
RQ 4 Treatment (radiation, no 
radiation (surgery, other 
treatment) 
Women diagnosed with 
cervical cancer  
RQ 5 Regions in U. S. Women diagnosed with 
cervical cancer  
 
 
The only participants for the study included the group of women diagnosed with 
cervical cancer between 1973 and 2012 in the United States. The radiation therapy (yes, 
no), two levels of testing (early, late), four categories of race (Black, White, Hispanics, and 
Asians), four levels of age groups (20-29, 30-39, 40-49, >50), and five regions ( Alaska, 
East, North plains, South West, Pacific coast) in United States constituted the independent 
variables. The dependent variable included two levels of survival rates (survived, not 
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survived). No identifiable time or resource constraints affected the outcome of the study. 
Conducting the study involved using secondary data that were available to the public 
SEER. The SEER data sets reliable, made available to the research community at no cost 
for carrying out research purposes for filling the gaps in cancer research (Kent et al., 2015).  
Research Design and Rationale 
Conducting the study required using a cross-sectional study. Cross-sectional study 
scholars estimate variations in the independent variables in the sample that researchers 
collected at a point in time (Miller, Prosser, & Thompson, 2015). The design was 
appropriate because there were three levels of treatment assessed in the study. The design 
was suitable because there was no randomization of the six treatment groups in the study. 
The goal was to determine the effectiveness of these three levels of treatments among six 
groups of women with cervical cancer. The treatment levels included (a) radiation therapy 
alone, (b) no radiation (but using other treatments such as chemotherapy alone and surgery 
alone), and (c) radiation therapy and surgery for women diagnosed with early stage or late 
stage cervical cancer. The design included testing whether there was a difference in 
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survival rates following radiation therapy in early detection of cervical cancer based on 
women’s ages by the group and race.  
 The cross-sectional study provided the design for investigating the benefits that 
women with cervical cancer get from treatment categories such as radiation, radiation with 
surgery, and treatment with no radiation based on treatment group, and control group. This 
study may fill the gap in the literature by examining what could occur when women 
undergo early screening for cervical cancer, obtain radiation therapy, and the effect on their 
survival rates (Question 1). It was not known whether women of particular age typically 
received early stage or late stage (Question 2). 
 In this study, I examined the effect of race on survival when contracted with 
cervical cancer (Question 3). This study provided information on the association between 
radiation treatment and survival of women with cervical cancer (Question 4), and the 
association between regions in United States and survival rates (Question 5).  
I used a cross-sectional design rather than a quasi-experimental design or 
experimental design. Quasi-experimental and experimental designs are evidence-based, 
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using cases and control demonstrating the most conclusive or causal findings related to the 
research outcomes (Cook, Tankersley, Cook & Landrum, 2015). Deater-Deckard (2016) 
argued that scholars use Quasi-experimental designs to test hypotheses about potential 
environmental effects, and they offer stronger inferences than correlational designs. On the 
contrary, cross-sectional study scholars cannot draw conclusions on causality due to a lack 
of random assignment of participants into groups (Bernstein et al., 2015; Dougados et al., 
2014). Hofmann and Patel (2015) argued that researchers use a cross-sectional study when 
a random selection of participants into groups to represent each section of the population is 
not possible.  
This study was a convenient placement of people into groups for early and late 
HPV testing and radiation therapy based on age and race. When researchers conduct 
research in which random placement of volunteers into groups is not possible, they perform 
perform a convenient selection of participants (Strandell-Laine, Stolt, Leino-Kilpi, & 
Saarikoski, 2015). The benefits of cross-sectional design are many in that it is inexpensive, 
and done within a short period (Ferguson, Rowlands, Olds, & Maher, 2015). Ferguson et 
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al. (2015) argued that cross-sectional study scholars can assess the prevalence of a disease 
because the sample represents the entire population. This study was a quantitative analysis 
of the data collected by SEER between 1973 and 2012 that included incidence of cervical 
cancer, population data, age, sex, race, geographical areas, years of diagnosis, and 
treatment modalities. To access the research data, however, I had to sign the research data 
agreement with SEER, no time, and resource constraints were associated with the 
collection of the data.   
Methodology 
Population 
The population for the study consisted of women diagnosed with cervical cancer in 
the United States between 1973 and 2012. The strategy for getting the sample from the 
population was random sampling strategy using the procedure of random sampling table. 
Researchers draw samples using two sampling strategies: a random sample from the 
population, and convenient sampling for age, race, and treatment (Stolar & Nielsen, 2015).  
Sampling Procedures 
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The sampling frame consisted of inclusion and exclusion criteria used for this study. 
Women included in the study were females diagnosed with cervical cancer between 1973 
and 2012. Men were excluded from the research. Women who were not diagnosed with 
cervical cancer but had breast and other cancers were also excluded from the study. 
Researchers conducted power analysis to determine the minimum sample size 
required so that the result is reliable. The interaction between sample size, α, effect size, 
and the p-value < .005 expresses the value of power (Cumming, 2013; Emerson, 2016). 
Researchers conduct power analysis to check whether a sample size could answer the 
research questions within the limits of time and money imposed (Albers, Boevé, & Meijer, 
2015). This study, consisted of six independent variables and one dependent variable. I 
conducted multiple logistic regression analysis. Madan, Lönnroth, Laokri, and Squire 
(2015) reported that scholars use logistic regression to determine the association between 
the independent variables and the dependent variable. Researchers use logistic regression 
analysis to identify a set of variables capable of maximizing prediction of the outcome 
variable (Tonidandel & LeBreton, 2015).  
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I used sample size calculation from OpenEpi., the confidence interval (CI) = 95%, 
the power (1-beta, % chance of detecting) = 80%, odds ratio = 2. The ratio of women with 
radiation therapy to women without radiation therapy (surgery only) was 1:2 (Alexandre et 
al., 2017). Using the Fleiss method, the total sample size in both exposed and unexposed to 
treatment = 1211 (Dean, Sullivan & Soe, 2013). I used all cases that met selection criteria 
for the sample size.  
In RQ 1, I used the data to analyze the association between early and late HPV 
testing and survival rates following treatment. In RQ 2, I examined the association between 
ages of the participants and the survival rate following treatment in early stage cervical 
cancer. In RQ 3, I analyzed the association between race and survival in early stage 
cervical cancer, while in RQ 4, I explained the association between treatment (radiation, 
and no radiation therapy) at the beginning of cervical cancer and survival rate. In RQ 5, I 
analyzed the association between regions of the United States where participants came 
from, and the occurrence of cervical cancer and survival rates. 
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Procedures for Recruitment, Participation, and Data Collection 
This study involved using the data set from SEER database. The SEER medical 
health outcomes (MHOs) databases use two large population-based sources of evidence of 
people with cancer. The two sources are SEER's cancer registries and MHOs (National 
Cancer Institute, n.d.). To access the SEER database, researchers must obtain the necessary 
permission starting with an online request, signing paperwork, and mailing it to the SEER 
headquarter for final processing. When approved, the SEER office e-mails the researcher a 
password and a username to gain access to the SEER database; an update is needed for the 
dissertation (National Cancer Institute, n.d. b).  
Data Analysis Plan 
I used secondary data from SEER for this study. The collection of the data 
involved an online request for the use of the data and SEER issuance of username and 
temporary password for the assessing the database following the approval. I  used SPSS to 
analyze the data because SPSS can accommodate large sample size and provide logical 
explanation relevant to the study. After the data collection, I performed data cleaning and 
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screening by removing items that were not pertinent to this study, and identifying the 
miscoded and missing data. The cleaning allows researchers to use the relevant data for the 
study and to ensure validation of the data (DeSimone, Harms, & DeSimone, 2015; 
Chibanda et al., 2016). Table 6 identifies the level of measurement of the outcome variable 
and the independent variables for this study. 
Table 6 
Relationship Between the Independent Variables, Level of Measurements, and Outcome 
Variable   
 
Variable  Research 
question             
Type  Level of 
Measurement   
Outcome 
variable 
Early 
testing/Late 
testing (year) 
RQ 1 Independent Categorical Survived, 
not 
survived 
Treatment 
(Radiation, no 
radiation) 
RQ 4 Independent Categorical Survived, 
not 
survived 
Age 
(20- 29, 30-39, 
40-49, >50) 
  
RQ 2 Independent Ordinal Survived, 
not 
survived 
Race 
(Black, non-
RQ 3 Independent Categorical Survived, 
not 
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Hispanic White, 
Hispanic, and 
Asians  
survived 
Regions in U. S. 
(Alaska, East, 
Northern Plains, 
South West, 
Pacific Coast )  
RQ 5 Independent Nominal Survived, 
not 
survived  
 
Data Analysis  
I used SPSS statistical software to analyze the data, calculate descriptive statistics 
and binary logistic regressions for the five research questions. The descriptive analysis 
included numerical data frequency followed by binary logistic regression analysis. In 
binary logistic regression, researchers can predict the probability of an event occurring or 
not occurring, to determine the association between one independent variable and the 
outcome (Babyar, Peterson, & Reding, 2016). Multiple logistic regression was used to 
predict the most parsimonious model for this study. I used logistic regression because the 
outcome variable was binary or categorical in nature.     
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Assumptions 
The assumptions in multiple logistic regressions are applicable to this study. The 
assumptions explained how the independent variables (early testing, late testing, race, age, 
radiation therapy) were associated with the dependent variable (survival rates). 
The independent of errors. There should be no relationship between the cases, indicating 
that researchers should not measure the same set of people at a different point in time 
(Hansen, Jeske, & Kirsch, 2015).  
Multicollinearity. The independent variables or predictors should not have a perfect linear 
relationship involving two or more independent variables. This Multicollinearity indicates 
that predictors should not demonstrate high correlation (Sheen, Spiby, & Slade, 2015). 
Table 7 
Relationship between variables, level of measurement and appropriate statistical tests 
 
Research question Variable/Level of 
Measurement 
Statistical tests 
RQ 1 Early HPV testing/Late 
HPV testing/ 
Categorical  
Binary logistic 
regression 
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RQ 2 Age/ Ordinal  frequency  
RQ 3 Race/ Categorical  Frequency 
RQ 4 Treatment/Categorical Binary logistic  
regression 
RQ 5 Regions/Nominal Frequency  
 
  
 
Threats to validity 
The study has validity threats. The selection of participants in the cross-sectional 
design allows for selection bias, which can affect the validity of the result. Oluyomi et al., 
(2015) reported that cross-sectional design is prone to validity threats. When researchers 
conduct research that covers a large section of the community in which random selection of 
the participants was not possible, there may be threat to the validity of the outcomes 
(Oluyomi et al., 2015). Yi, Chhoun, Suong, Thin, Brody, & Tuot (2015) argued that 
selection bias resulted in some segments of the population under study than the others, and 
affects the internal validity of the study. The threat to internal validity can lead to a threat 
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to external validity, and the outcome may not represent the characteristics of the 
community.      
Summary and Transition 
Cervical cancer is a chronic disease that is preventable when detected early through 
Papanicolaou (Pap) test, HPV DNA test, and the use of HPV vaccines (Subramanian et al., 
2016). Since the introduction of radiation therapy, the researchers are yet to investigate the 
benefits of radiation therapy in early stage cervical cancer (Torre et al., 2015), despite the 
advantages of radiation therapy in increasing survival in other cancer diseases (Landry et 
al., 2015).    
In this chapter, I reviewed the research design and rationale for the study to 
understand the association between the use of radiation alone or in combination with 
surgery and survival of women diagnosed with cervical cancer. This chapter also focused 
on the review of research questions, and the hypotheses, the methodology, and the threats 
to the validity of the study. In chapter four, I present the introduction to chapter four, the 
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data collection, and the treatment and intervention. Chapter 4 included the results analysis, 
summary, and transition to chapter five. 
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 Chapter 4: Results  
Introduction 
The purpose of the study was to investigate the association between radiation 
therapy and early cervical cancer detection among women in the United States based on 
age, race, and regions. I analyzed secondary data from the SEER between 1973, and 2012. 
Five research questions and hypotheses were tested.  
RQ1: What is the association between testing (early HPV VS late HPV) and 
survival rate of women when diagnosed with Stage IA to IIA cervical l cancer? 
Ho1: There is no association between testing (early HPV VS late HPV) and survival 
rate of women when diagnosed with Stage IA to IIA cervica l cancer? 
Ha1: There is an association between testing (early HPV VS late HPV) and survival 
rate of women when diagnosed with Stage IA to IIA cervica l cancer? 
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RQ2: What is the association between age and survival rates of women when 
diagnosed with Stage I to IIa cervical cancer?  
Ho2: There is no association between age and survival rates of women when 
diagnosed with Stage I to IIa cervical cancer.  
Ha2: There is an association between age and survival rates of women when 
diagnosed with Stage I to IIa cervical cancer.  
RQ3: What is the association between race and survival rates when diagnosed with 
Stage I to IIa cervical cancer? 
 H03: There is no association between race and survival rates when diagnosed with 
Stage I to IIa cervical cancer. 
  Ha3: There is an association between race and survival rates when diagnosed with 
Stage I to IIa cervical cancer.  
RQ4: What is the association between radiation therapy and survival rates of 
women when diagnosed with Stage I to IIa cervical cancer? 
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H04: There is no association between radiation therapy and survival rates of women 
when diagnosed with Stage I to IIa cervical cancer. 
Ha4: There is an association between radiation therapy and survival rates of women 
when diagnosed with Stage I to IIa cervical cancer. 
 RQ5: What are the associations between five regions in the United States and 
survival rates of women when diagnosed with Stage I to IIa cervical cancer.  
H05: There are no associations between five regions in the United States and 
survival rates of women when diagnosed with Stage I to IIa cervical cancer. 
Ha5: There are associations between five regions in the United States and survival 
rates of women when diagnosed with Stage I to IIa cervical cancer.  
In this chapter, I will first discuss the data collection process for the study as well as 
reporting baseline descriptive and demographic characteristics of the sample. Assumptions 
such as examination of outliers will be addressed. Next, the results of the analysis will be 
discussed by first providing frequencies for categorical data and descriptive statistics for 
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quantitative data. The results of the analysis will be organized by each research question 
and hypotheses. Lastly, the results of this chapter will be summarized in the summary.   
Data Collection 
Conducting the study involved using the data set from the SEER database. To gain 
access, SEER granted permission, both username and password were e-mailed to me. The 
original dataset contained both males and females of varying demographics; however, only 
females of at least 20 years of age were included in the study. There were 520,153 females 
in the study. Sixteen thousand seven hundred and twenty-five (16,725, 3.2%) were ages 
20–29; 41,594 (8%) were ages 30–39; 82,617 (15.9%) were ages in 40–49 and 399,217 
(72.9%) were older than 50 years. There were 448,739 (86.3%) Whites and 66,918 
(12.9%), and non-Whites with 4,496 (0.9%) were missing. U.S regions included 499 (.1%) 
Alaska; 173,932 (33.4%) East; 76,990 (14.8%) Northern Plains; 32,595 (6.3%) Southwest; 
and 236,137 (45.4%) Pacific Coast. Table 8 below summarizes this information. 
Table 8 
 
Demographic Characteristic of Study Variables 
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Variable Frequency Percentage 
Females 520,153 100% 
Age: 
20 – 29 
30-39 
40 – 49 
>50 
Total N: 
 
16,725 
41,594 
82,617 
399,217 
520,153 
 
3.2% 
8% 
15.9% 
72.9% 
100% 
Race: 
White 
Non-White 
Missing 
Total N: 
 
 
 
448,739 
66,918 
4496 
520,153 
 
86.3% 
12.9% 
0.9% 
100% 
U.S Region: 
Alaska 
East 
Northern Plains 
Southwest 
Pacific Coast 
Total N: 
 
 
499 
173,932 
76,990 
32,595 
236,137 
520,153 
 
0.1% 
33.4% 
14.8% 
6.3% 
45.4% 
100% 
Of the 520,153 subjects, 257,757 (49.6%) were still alive and 262,396 (50.4%) 
were deceased. In addition, 68.6% did not receive radiation therapy and 28.8% did receive 
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radiation therapy. I found that 28.8% had early HPV testing and 68.6% were late in testing 
(Table 9 below).  
 
 Table 9 
 
Vital Statistics, Radiation Therapy and HPV Testing 
 
Variable Frequency Percent 
Vital Status: 
Alive 
Dead 
Total 
  
257,757 
 
49.6% 
 262,396 50.4% 
 520,153 100.0% 
Radiation: 
Yes 
No 
Missing 
Total 
  
149,985 
356,578 
13,590 
520,153 
 
28.8% 
68.6% 
2.6% 
100% 
HPV Testing: 
Early Testing 
Late Testing 
Total 
  
140,936 
379,217 
520,153 
 
28.8% 
68.6% 
100% 
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I assumed that the secondary data collected from SEER wee reliable and could 
generalize the cervical cancer statistical data obtained if collected by any other agencies. 
The delimitation of the study was to participants living in the United States, and the result 
may not be generalizable to countries beyond the United States.  
Results 
I conducted binary logistic regression to study the relationships between type of 
therapy (radiation/no-radiation), age of diagnosis, stage type (early/late), race, U.S. regions, 
and survival rates of females with cervical cancer. In the first research question, I examined 
the relationships between testing (early HPV VS late HPV) and survival rates. 
A one-unit increase in early HPV testing (i.e. [early] testing) resulted in decreased 
odds of dying by .917. Individuals who had late testing had an increased odds of 1/.917 = 
1.0905 of dying compared to those who had early testing. Individuals who had radiation 
had an increased likelihood of 1.646 of dying; for every year of increase of age at 
diagnosis, the odds of dying increased by 1.043; Whites had a decreased odds of death by 
.735. Non-whites had an increased odds of 1/.735 = 1.3605 of dying compared to Whites. I, 
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therefore, rejected the null hypothesis that says that there is no association between testing 
(early HPV VS late HPV) and survival rate of women when diagnosed with Stage IA to 
IIA cervical cancer. Table 10 below provides the odds ratio and confidence intervals. 
Table 10 
Logistic Regression Predicting Survival Rates From Early HPV testing 
 
 B  S.E. Wald df Sig. Exp(B) 95% C.I.for 
EXP(B) 
Lower Upper 
   Early 
HPV 
Testing  
 -.086    
.012 
52.68
5 
1 .000 .917 .896 .939 
      
Constant 
-
2.202 
    
.030 
 
5399.
787 
1 .000 .111   
a. Variable(s) entered on step 1: Early HPV Testing at diagnosis. 
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In the second research question, I investigated the relationship between age and 
survival rates. 
The binary logistic regression was statistically significant, χ2(1) = 30940.69, p < .005. The 
Nagelkerke R square was .077; thus, this explained 7.7% of the variation in survival rate 
from age. Age at diagnosis was statistically significant (p < .005). For every year of 
increase, there was an increased odds of death by 1.045 times. I, therefore, rejected the null 
hypothesis that says that there is no association between age and survival rates of women 
when diagnosed with Stage I to IIa cervical cancer. Table 11 below provides odds ratios as 
well as 95% confidence intervals.  
Table 11 
Logistic Regression Predicting Survival Rates From Age at Diagnosis 
 
 
 B S.E. Wal
d 
df Sig. Exp(B) 95% C.I.for 
EXP(B) 
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Lower Upper 
Step 
1
a
 
Age at 
diagnos
is 
.04
4 
.000 2837
1.49
6 
1 .000 1.045 1.045 1.046 
Constan
t 
-
2.4
42 
.015 2663
6.81
8 
1 .000 .087   
Note. a. Variable(s) entered on step 1: Age at diagnosis. 
 
  
 For research question 3, I used logistic regression to investigate the 
association between race and survival rates. The predictor was statistically significant, χ2(1) 
= 552.27, p < .005. The Nagelkerke R square was .001, and it explained only 0.1% of the 
variation in survival rate from race. Race was a statistically significant predictor. Non-
White females had an increased chance of dying than White females by 1/.823 = 1.215 
times when diagnosed with Stage I to IIa cervical cancer. I found that non-Whites (Black) 
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had higher risk of developing cervical cancer. I, therefore, rejected the null hypothesis that 
says that there is no association between race and survival rates of women when diagnosed 
with Stage I to IIa cervical cancer. Table 12 below has information regarding odds ratios 
and confidence intervals.  
Table 12 
Logistic Regression Predicting Survival Rates  From Race 
 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
 Race -.195 .008 550.12
0 
1 .000 .823 .809 .836 
Const
ant 
.201 .008 670.16
1 
1 .000 1.223   
Note. a. Variable(s) entered on step 1: Race. (Note: For non-White females, Race = 0. 
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White females, Race = 1). 
 
For Research Question 4, I explored the relationship between radiation therapy and 
survival rates. Logistic regression was used to investigate the relationships between 
radiation therapy and survival rates. The predictor was statistically significant, χ2(1) = 
5770.91, p < .005. The Nagelkerke R square was .015; thus, the binary logistic regression 
explained 1.5% of the variation in survival rate from radiation therapy. Individuals who had 
radiation therapy were 1.600 times likely to have died than those with nonradiation 
treatments. I, therefore, rejected the null hypothesis that says that there is no association 
between radiation therapy and survival rates of women when diagnosed with Stage I to IIa 
cervical cancer. Table 13 below has more detailed information on odds ratios and 95% 
confidence intervals.  
Table 13 
Logistic Regression Predicting Survival Rates From Radiation Therapy 
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 B S.E. Wald df Sig. Exp(B) 95% C.I.for 
EXP(B) 
Lower Upper 
 Radia
tion 
.470 .006 5711.252 1 .000 1.600 1.581 1.620 
Const
ant 
-.138 .003 1698.838 1 .000 .871   
Note. a. Variable(s) entered on step 1: Radiation. 
 
In Research Question 5, I explored the association between U.S regions and 
survival rates. The binary logistic regression was statistically significant, χ2(4) = 146.56, p 
< .005. U.S region was a statistically significant predictor of cervical cancer survival. I 
used binary logistic regression analysis to determine the association between five regions 
(independent variables) and survival rates (dependent variable) of women with cervical 
cancer. The nature of the variables is categorical, and this dictated the analysis.  
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Compared to the Pacific Coast, females in Alaska had a decreased likelihood of 
dying by .714 times. Females in the Pacific Coast were 1.4005 times as likely to die when 
diagnosed with Stage I to IIa cervical cancer. Compared to the Pacific Coast, females who 
resided in the Eastern region of United States had an increased likelihood of dying by 1.044 
times when diagnosed with Stage I to IIa cervical cancer. Females who resided in the 
Northern plains had a decreased likelihood by .997 of dying when diagnosed with Stage I 
to IIa cervical cancer (compared with females in the Pacific Coast). Females who resided in 
the Southwest had a decreased likelihood of dying by .918 when diagnosed with stage I to 
IIa cervical cancer (compared with females in the Pacific coast). I, therefore, rejected the 
null hypothesis that says that there is no association between regions in the United States 
and survival rates of women when diagnosed with Stage I to IIa cervical cancer. Table 14 
below has more detailed information on odds ratios and 95% confidence intervals.  
Table 14  
Logistic Regression Predicting Survival Rates From U.S Region 
 
 B S.E. Wald df Sig. Exp( 95% C.I.for 
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B) EXP(B) 
Lower Upper 
 U.S 
Region 
Code 
  146.286 4 .000    
Alaska(1) -.337 .091 13.761 1 .000 .714 .598 .853 
East(2) .044 .006 47.441 1 .000 1.044 1.032 1.058 
Northern 
Plains(3) 
-.003 .008 .131 1 .718 .997 .981 1.013 
Southwest
(4) 
-.085 .012 52.071 1 .000 .918 .897 .940 
Constant .009 .004 5.208 1 .022 1.009   
Note: Reference category is Pacific Coast 
 
Modeling 
This is the full multiple logistic regression (MLR) including all variables to predict 
the most parsimonious model. The result was statistically significant, χ2(4) = 36441.89, p < 
.005. The Nagelkerke R square increased to .093; thus, the result explained 9.3% of the 
variation in survival rate by including both demographic variables as well as radiation 
therapy and early HPV testing. Table 15 below provides odds ratios as well as 95% CIs for 
these coefficients. All predictors were statistically significant (p < .005).  
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There were no studentized residuals larger than 2.5; therefore, there were no 
outliers in the data set. The full model included all of the variables, and was it statistically 
significant, χ2(2) = 30309.82, p < .005. The Nagelkerke R square was .078; thus, this model 
explained 7.8% of the variation in survival rate from the demographic variable of age (p < 
.005). The model had 7.8% variation in survival rate for race (Nagelkerke R square = .078, 
p < .005).      
 
 
 
 
Table 15 
Logistic Regression Predicting Survival Rates From Race, Age at Diagnosis,  
Radiation Therapy and Early HPV testing 
 
 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for 
EXP(B) 
Effect 
size 
Low
er 
Uppe
r 
(ES) 
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 Race -.308 .009 1225.361 1 .000 .735 .722 .748 -.170 
Age at 
diagno
sis 
.042 .000 8006.604 1 .000 1.043 1.04
2 
1.044 .042 
Radiati
on 
.499 .006 5980.917 1 .000 1.646 1.62
6 
1.667 .275 
Early 
HPV 
Testing 
-.086 .012 52.685 1 .000 .917 .896 .939 
 
-.048 
U. S. 
Region
s 
-.088 .017 63.264 1 .000 .831 .772 .865 
 
.101 
 Consta
nt 
-
2.202  
.030 5399.787 1 .000 .111    
 
Summary  
I performed binary logistic regression in order to investigate the association 
between early HPV testing, radiation therapy, age, race, U.S. region, diagnosis, and 
survival rates of women when diagnosed with Stage I to IIa cervical cancer. In the first 
research question, I investigated the association between early HPV testing and survival 
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rates for women diagnosed with early Stage IA to IIA cervical cancer. No outliers detected 
in the data set by inspection of studentized residuals.  
All predictors were statistically significant (p < .005). Individuals who had early 
HPV testing resulted in a decreased odds of dying. Individuals who had late HPV testing 
had an increased likelihood of dying compared to those who had early testing. I rejected the 
null hypothesis that there is no association between early versus late testing and survival 
rates of women diagnosed with Stage I to IIa cervical cancer. In Research Question 2, 
investigated the association between ages and survival rates of women when diagnosed 
with Stage I to IIa cervical cancer. The overall model was statistically significant. Age at 
diagnosis was statistically significant. For every year of increase, there was an increased 
odds of death. I therefore, rejected, the null hypothesis that there is no association between 
ages and survival rates of women when diagnosed with Stage I to IIa cervical cancer. 
In Research Question 3, I examined the association between race and survival rates 
when diagnosed with Stage I to IIa cervical cancer. The overall model was statistically 
significant. Race was a statistically significant predictor. Non-White females had an 
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increased chance of dying compared to White females by 1.215 times when diagnosed with 
Stage I to IIa cervical cancer. I, therefore, rejected the null hypothesis that there is no 
association between race and survival rates of women when diagnosed with Stage I to IIa 
cervical cancer. In Research Question 4, I investigated the association between radiation 
therapy and survival rates of women when diagnosed with Stage I to IIa cervical cancer. 
The overall model was statistically significant. Individuals who had radiation therapy were 
more likely to have died than those with non-radiation treatments.  
 In Research Question 5, I explored the associations between regions in the United 
States and survival rates of women when diagnosed with Stage I to IIa cervical cancer. The 
predictor was statistically significant. U.S. region was a statistically significant predictor. 
Compared to the Pacific Coast, females in Alaska had a decreased odds of dying when 
diagnosed with Stage I to IIa cervical cancer. Compared to the Pacific Coast, females who 
resided in the Eastern region of United States had an increased odds of dying when 
diagnosed. Females who resided in the Northern plains had a decreased likelihood of dying 
when diagnosed with Stage I to IIa cervical cancer (compared with females in the Pacific 
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Coast). Females who resided in the Southwest had a decreased likelihood of dying when 
diagnosed with Stage I to IIa cervical cancer (compared with females in the Pacific coast). 
I, therefore, rejected the null hypothesis that there is no association between regions in 
United States. and survival rates of women when diagnosed with Stage I to IIa cervical 
cancer. Table 16 below explains the association between the variables, the findings, and the 
null hypothesis. 
Table 16 
 
Table Summarizing Findings, Significance, and Null Hypotheses 
 
Variables Clinical findings Sig. Reject/failed 
to reject null 
hypothesis 
Early HPV Testing Improve survival P < .005 1 
Radiation therapy Did not improve 
survival 
P < .005 1 
Age Younger age at 
diagnosis  Increase 
survival 
P < .005 1 
Race Some races Improve 
survival 
P < .005 1 
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Regions In U. S. Some regions in U. 
S. Improve survival 
P < .005  1 
Note. Reject null hypothesis – 1, failed to reject null hypothesis = 0, null hypothesis = no 
association 
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Chapter 5: Conclusion 
Epidemiologists have under researched the benefits of using radiation therapy for 
treating women with early cervical cancer detection. Globally, for every 530,000 diagnoses 
of cervical cancer, 275,000 people died, demonstrating a survival rate of only 48% 
annually (Pimenta et al., 2013). There had been a steady improvement in cancer survival in 
the United States, but the improvement in relation to age, sex, and race remains 
unaccounted for in the current literature (Zeng et al., 2015).  
I conducted this study among women diagnosed with early staged cervical cancer to 
investigate the association between testing (early versus late testing HPV), age, race, 
radiation therapy, and regions in the United States (independent variables), and survival 
rates (dependent variable). I used secondary data from SEER. Currently, there is a dearth of 
information on the effects of treating early stage cervical cancer with radiation for 
increasing patient survival among different age groups and races in the United States.  In 
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this cross-sectional study, I used a sample size of 520,153 participants. Statistical analyses 
included descriptive statistics and binary logistic regression using SPSS.  
Some women received screening early in life, but did not undergo subsequent 
screenings because of a lack of mechanisms in place to receive additional screenings. There 
is limited existing research on the effects of early testing and related early radiation therapy 
on survival rates among women. Researchers found that using radiation therapy in early 
breast and lung cancer treatment in the United States was effective for respective survival 
rates. However, such information is lacking for using radiation therapy for treating early 
cervical cancer stages among women in the United States compared to surgery alone 
(Robinson et al., 2014).  
The purpose of this quantitative, cross-sectional study was to examine the 
association between radiation therapy (yes, no) and early detection of HPV (early HPV vs 
late HPV testing), race (four categories), age (four groups), five U.S. regions as the 
independent variables and survival rates (two classes) as the outcomes. Researchers need to 
understand the effects of radiation treatment on early stage cervical cancer based on 
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women’s age by group and race. The intent of this study was to add to the body of 
knowledge and to close a gap in the literature on the effects of treating early cervical cancer 
with radiation and survival rates among women in the United States.  
Summary of Findings 
In this study, early HPV testing resulted in decreased odds by .917, and women who 
had late testing had increased odds of 1/.917 = 1.0905 of dying. The effect size for early 
HPV testing was -.048 (negative effect size) the significant p value did explain how well 
the early HPV testing would improve survival of women from cervical cancer. The early 
HPV testing was a strong predictor of survival from cervical cancer. I examined the age at 
diagnosis, the odds of dying increased by 1.043; the effect size was .042, which is a 
positive effect size, and signified a strong predictor of survival from cervical cancer. Race 
was a predictor of survival from cervical cancer; the effect size for race was -.170. The 
significant level of p value indicated that race was a meaningful and strong predictor of 
survival from cervical cancer. Individuals who had radiation therapy had an effect size of 
.275. A positive effect size of .275 supported the significance of p value of less than .005, 
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and the radiation was a strong predictor of survival for women when diagnosed early from 
cervical cancer.  
In this study, I found U. S. Regions to be a strong and meaningful predictor of 
survival from cervical cancer. The effect size for U. S. Regions was .101, a positive effect 
size, and a significant p value of less than .005.   
Strongest and More Meaningful Predictors 
The two levels of testing (early, late), radiation therapy (yes, no), four categories of 
race (Black, White, Hispanics, and Asians), four levels of age groups (20-29, 30-39, 40-49, 
>50), and five regions (Alaska, East, Northern Plains, South West, Pacific Coast) in the 
United States constitute the independent variables. The dependent variable was two levels 
of survival rates (survived, not survived). The five predictors are meaningful, and are 
strong predictors of survival from cervical cancer. Early HPV testing had 91.7 percent 
decrease in odds of dying, and for each year increase in age at diagnosis there was 104 
percent odds of dying. White women had an 82 percent increase odds of dying from 
cervical cancer, while non-White women had 122 percent odds of dying from cervical 
122 
 
 
 
percent odds of dying from cervical cancer. Women with radiation therapy had160 percent 
increased odds of dying than women without radiation therapy. The U. S. regions are 
meaningful and strong predictors of survival from cervical cancer. Women in Alaska had 
71 percent decreased odds of dying from cervical cancer, while women in the Pacific Coast 
had 140 percent increase odds of dying  
    Interpretation of the Findings 
The United States is not an exception in the global persistence of cervical cancer. 
The incidence of cervical cancer was on the rise among younger women in the United 
States with poor clinical outcomes, despite the knowledge, prevention, and treatment 
modalities for the causative organism (Wang et al., 2014). Fleming et al. (2014) argued that 
there was unequal treatment after early detection of cervical cancer. Some women received 
radiation; others received surgery, and there were no data on control variables such as a 
race on radiation therapy.  
Researchers have demonstrated that early testing for cervical cancer could speed up 
the treatment of cervical cancer, and late HPV testing worsened the diagnosis, a finding 
123 
 
 
 
confirmed by this study’s results. Sankaranarayanan (2014) stated that HPV testing offered 
early detection of precancerous lesions of the cervix, and cancerous lesions if women 
present late. Benard et al. (2014) reported that early HPV and Pap tests are useful to 
determine the health status of a woman before or during HPV infection and the 
development of cervical cancer, and they are the sources of education for women 
concerning the disease. Benard et al. stated that the HPV and Pap tests provide evidence-
based screening practices for cervical cancer, and they help to prevent precancerous lesions 
from progressing to invasive cervical cancer.  
Logistic regression analysis, however, revealed that women with early detection of 
cervical cancer had an increased likelihood of dying with radiation therapy. Some previous 
researches revealed that radiation therapy led to complications that resulted in death 
(Vaidya et al. 2014). Vaidya et al. reported that women who received radiation therapy for 
early breast cancer had cardiovascular complications that resulted in death. Hurem et al. 
(201) argued further that reduction in survival from radiation therapy resulted from 
oxidative stress or genetic damage in the living organism.   
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Some exceptions to cervical cancer screening occur. Exceptions include women 
with two consecutive negative Pap and HPV tests within the last ten years or women who 
had a hysterectomy (Saslow et al., 2012). Also, Smith et al. (2015) stated that the criteria 
for an exception were for women older than 65 years of age and women with three 
consecutive negative Pap smear tests. These women did not need screening for the HPV 
and cervical cancer. Researchers argued that SES is an important factor in determining 
when some women were likely to engage cervical cancer screening (Tervonen et al., 2016).    
Perkins and Stier (2014) explained that HPV testing had higher sensitivity than Pap 
tests and that HPV test detects 95% of HPV, while Pap test detects about 40-70% of HPV. 
When the physicians asked for the two tests, the detection rate increased above 95%. 
Perkins and Stier stated that early HPV and Pap tests detect precancerous lesions before 
progression to invasive lesions detected by late HPV testing, and early HPV and Pap tests 
reduce the incidence by 50%. The risk of developing cervical cancer or cervical dysplasia 
after three years of negative Pap test is .78%, after three years of negative HPV test is .34% 
and after three years for both Pap and HPV tests was .30% (Perkins & Stier, 2014). Women 
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with late testing and women missing their testing dates progressed to cancerous lesions if 
there were preexisting precancerous lesions (Perkins & Stier, 2014).  
Participation in screening for cervical cancer among women in developed countries 
was not as high as possible. Researchers believed that 42% of women in the United States 
did not engage in early screening (Cohen et al., 2016). Cohen et al. argued that the 
screening rates among women varied by region in the United States and by age. The 
researchers indicated that 44% to 81% of women between the ages 45 and 64 underwent 
early screening.  
Approximately 67% of the women did not adhere to the U.S. screening 
recommendations, indicating a high level of non-adherence among U.S. women, despite 
awareness of screening centers on a nationwide level (Cohen et al., 2016). Despite the 
available knowledge of causative organisms of cervical cancer and effective treatment 
modalities, there remains inadequate awareness of the effectiveness of using radiation 
therapy among women of all races and ages that undergo early screening in the United 
States (Chen, Kessler, Mori, & Chauhan, 2012). Researchers have argued that there is a 
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benefit from increasing the number of women that undergo early (under age 40) cervical 
cancer screening because these researchers have observed an increase in nulliparous 
women diagnosed with early cervical cancer ( Choi et al., 2015).  
In this study, I found that age was an important predictor of cervical cancer. Smith 
et al. (2015) reported that age was important in the development of the cervical cancer, and 
the screening procedures were Pap smear tests and HPV DNA tests for women between 21 
to 65 years old. Saslow et al. (2012) argued that screening must start at age 21 and that 
women between 21 and 29 years old must receive screening every three years using a Pap 
test. Women who were 30-65 years old must screen for HPV using the Pap smear and HPV 
DNA tests every five years. Some women must screen every three years using the Pap 
smear test alone (Park et al., 2015). Screening should continue for 20 years after the 
treatment for CIN2, CIN3, and adenocarcinoma in situ (Saslow et al., 2012).   
The treatment modalities for early cervical cancer are surgery and radiation. In this 
study, radiation was not a strong predictor of survival from cervical cancer. Treatment for 
cervical cancer is effective and can be cured when detected early, and the prognosis of 
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cervical cancer depends on the staging (Lau et al., 2015). Radiation therapy alone or in 
combination with another therapy has increased survival in many diseases such as lung, 
breast, and colorectal cancers (Landry et al., 2015). Researchers have noted the disparities 
in the outcomes of the use of radiation therapy for breast cancer among different age 
groups and races (Powers et al., 2015). There is a lack of information on the benefit of 
using radiation therapy in cervical cancer in early age groups and races and needs to be 
further studied (Fang et al., 2015).  
Surgery is one of the recommended treatment modalities for addressing early stage 
cervical cancer in women, a finding confirmed by this study’s results, which determined 
that there were higher death rates from radiation alone as opposed to other treatment 
modalities. Shazly, Murad, Dowdy, Gostout and Famuyide (2015) revealed that surgery is 
of importance, but there is a lack of evidence to support the effectiveness of surgery for 
early cervical cancer. Pareja et al. (2015) argued that surgeons used radical trachelectomy 
or cervicectomy (removal of cervix only to preserve fertility in young women who may 
want to bear children).  
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The theory of epidemiological triad of disease model was the theoretical framework 
for the study. According to Cohen and Shang (2015), Clark (1954) developed the 
epidemiological triad to explain a spatiotemporal relationship between three areas known 
as the agent, the host, and the environment. Cohen and Shang found that Clark's theory was 
useful for breaking disease transmission by predicting the agent (procedures such as early 
HPV - testing), the host (age and race), and the environment or place (regions in U. S.). 
Cohen and Shang believed that a triad was a form of isolation precautions useful for the 
control of infectious diseases with increased morbidity and mortality outcomes.  
The theory is useful when testing multiple interventions based on specific 
pathogens in a cross-sectional study such as this one. Rohrer, Grover and Moats (2013) 
applied the epidemiological triad to medical care studies and further argued that there is a 
benefit for researchers to use variations of the theory to person, place, and time associated 
with the theoretical model. Chaney and Rojas-Guyler (2015) argued that a triad is a tool 
that explained health promotion, educational research, and practice.  
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Theoretical implication of this study 
In this study, the epidemiological triad of person, place, and time helped in 
educating people about disease spread and prevention. Chaney and Rojas-Guyler (2015) 
reported that age, race, and place influenced the decision of the people to use drugs 
(marijuana, tobacco, and alcohol). I found some places to be high and low risk areas for 
both races to develop cervical cancer, variations in the awareness for early HPV testing 
among women in U. S. regions, and this led to variations in survival rates from cervical 
cancer in United States.  
   Limitations of the Study 
This study examined the secondary data from SEER database for women that used 
or did not use radiation for early cervical cancer. This study was limited to participants 
living in the United States, and may not be generalizable to countries beyond the United 
States. This study does not apply to women who developed early cervical cancer from in-
utero exposure to diethylstilbestrol, organ transplant or the use of chemotherapy such as 
chronic use of corticosteroid. This study did not identify which HPV types were in the 
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secondary data. The secondary data collected from SEER could not assume a causal role 
because the data were not primary data, and could only measure associations between 
independent and dependent variables.  
   Recommendations for Future Research 
The main recommendations for future research center on the prevention of the 
development of cervical cancer and raising awareness of the importance of early testing 
among young women, especially those from vulnerable populations, such as non-White 
women in the United States. As cervical cancer is a disease with high death rates 
throughout the world, researchers need to replicate similar studies in other nations, 
particular those in the developing world where researches are less conducted. Age, race, 
and regions are variables the researchers should consider in studies of early versus late 
testing.   
Implications of the Findings 
The findings of this study offer no support for promoting radiation therapy.  
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This study would be a source of information for policy makers to customize programs that 
will encourage women to undertake early cervical cancer screening, and provide additional 
source of information for health care professionals. The findings from this study may 
motivate women to seek screening and treatment for early cervical cancer cases. This study 
would be a source of health education for non-Hispanic Blacks, White non-Hispanics, 
Hispanics, and Asians to correct any misperception about early screening for cervical 
cancer, radiation therapy, and similar survival rates.  
The results of this study add to the body of knowledge in epidemiology for 
understanding the effects of radiation for treating early stage cervical cancer for non-
Hispanic Blacks, White non-Hispanics, Hispanics, and Asians living in the United States. 
This study contributed to social change by providing evidence for women for getting 
regular Papanicolaou tests (Pap smears) and cervical cytology tests early in life. The results 
of this study can contribute to positive social change if early detection of cervical cancer 
proves to reduce mortality among women who otherwise succumb to the disease. A 
positive social change from this study is that the results would help to keep families 
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together and provide a better quality of life for women who receive early testing and that 
women with cervical cancer have the knowledge that radiation therapy may increase the 
likelihood of death in some patients.  
Overall, this study’s findings are consistent with the theoretical framework of the 
epidemiological triad, and help advance quantitative, cross-sectional methodological 
approaches. As noted public health researchers, as well as female patients and their 
physicians may be interested in knowing and acting on this study’s findings in relation to 
early testing and the use of radiation therapy.  
   Summary and Conclusions 
To conclude, this cross-sectional, quantitative study’s results have shown that early 
testing for cervical cancer reduces death rates, and that higher rates of death from the 
disease are associated with older age, radiation therapy, non-White race, and women 
residing on the East Coast and Pacific Coast of the United States. The epidemiological triad 
was a useful theoretical framework for this study. I hope that this study’s findings will help 
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raise awareness of the importance of early testing to reduce death rates from cervical 
cancer.  
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